

# A novel computational pipeline for *var* gene expression augments the discovery of changes in the *Plasmodium falciparum* transcriptome during transition from *in vivo* to short-term *in vitro* culture

## Reviewed Preprint

Revised by authors after peer review.

About eLife's process

## Reviewed preprint version 2

December 22, 2023 (this version)

## Reviewed preprint version 1

June 8, 2023

## Posted to preprint server

March 24, 2023

## Sent for peer review

March 21, 2023

Clare Andradi-Brown, Jan Stephan Wichers-Misterek, Heidrun von Thien, Yannick D. Höppner, Judith A. M. Scholz, Helle Hansson, Emma Filtenborg Hocke, Tim-Wolf Gilberger, Michael F. Duffy, Thomas Lavstsen, Jake Baum, Thomas D. Otto, Aubrey J. Cunningham ✉, Anna Bachmann ✉

Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, UK • Department of Life Sciences, Imperial College London, South Kensington, London, SW7 2AZ, UK • Centre for Paediatrics and Child Health, Imperial College London, UK • Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany • Biology Department, University of Hamburg, Hamburg, Germany • Center for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark • Department of Infectious Diseases, Copenhagen University Hospital, 2200 Copenhagen, Denmark • Department of Microbiology and Immunology, University of Melbourne, Melbourne/Parkville VIC 3052, Australia • School of Biomedical Sciences, Faculty of Medicine & Health, UNSW, Kensington, Sydney, 2052, Australia • School of Infection & Immunity, MVLS, University of Glasgow, UK • German Center for Infection Research (DZIF), partner site Hamburg-Borstel-Lübeck-Riems, Germany

 [https://en.wikipedia.org/wiki/Open\\_access](https://en.wikipedia.org/wiki/Open_access)

 Copyright information

## Abstract

The pathogenesis of severe *Plasmodium falciparum* malaria involves cytoadhesive microvascular sequestration of infected erythrocytes, mediated by *P. falciparum* erythrocyte membrane protein 1 (PfEMP1). PfEMP1 variants are encoded by the highly polymorphic family of *var* genes, the sequences of which are largely unknown in clinical samples. Previously, we published new approaches for *var* gene profiling and classification of predicted binding phenotypes in clinical *P. falciparum* isolates (Wichers *et al.*, 2021), which represented a major technical advance. Building on this, we report here a novel method for *var* gene assembly and multidimensional quantification from RNA-sequencing that outperforms the earlier approach of Wichers *et al.*, 2021 on both laboratory and clinical isolates across a combination of metrics. Importantly, the tool can interrogate the *var* transcriptome in context with the rest of the transcriptome and can be applied to enhance our understanding of the role of *var* genes in malaria pathogenesis. We applied this new method to investigate changes in *var* gene expression through early transition of parasite isolates to *in vitro* culture, using paired sets of *ex vivo* samples from our previous study, cultured for up to three generations. In parallel, changes in non-polymorphic core gene expression were investigated. Modest but unpredictable *var* gene switching and convergence towards *var2csa* were observed in culture, along with differential expression of 19% of the core transcriptome between paired *ex vivo* and generation 1 samples. Our results cast doubt

on the validity of the common practice of using short-term cultured parasites to make inferences about *in vivo* phenotype and behaviour.

### eLife assessment

Focusing mainly on var genes, the investigators performed comprehensive computational analyses of gene expression in malaria parasites isolated from patients and assessed changes that occur as these parasites adapt to *in vitro* culture conditions. The study provides an improved computational pipeline for monitoring var gene expression, and importantly, the study documents changes in expression of the core genome and thus provides insights into metabolic adaptations that parasites undergo while transitioning to culture conditions. The findings are **important** for their technical advances that are more rigorous than the current state-of-the-art. The **solid** data analyses, broadly support the claims with only minor weaknesses, tell us to be cautious when interpreting results obtained only from cultured parasites.

## Introduction


Malaria is a parasitic life-threatening disease caused by species of the *Plasmodium* genus. In 2021, there were an estimated 619,000 deaths due to malaria, with children under 5 accounting for 77% of these (WHO, 2022 [↗](#)). *Plasmodium falciparum* causes the greatest disease burden and most severe outcomes, but our efforts to combat the disease are challenged by its complex life cycle and its sophisticated immune evasion strategies. *P. falciparum* has several highly polymorphic variant surface antigens (VSA) encoded by multi-gene families, with the best studied high molecular weight *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) family of proteins known to play a major role in the pathogenesis of malaria (Leech *et al.*, 1984 [↗](#), Wahlgren *et al.*, 2017 [↗](#)). About 60 polymorphic *var* genes per parasite genome encode different PfEMP1 variants, which are exported to the surface of parasite-infected erythrocytes, where they mediate cytoadherence to host endothelial cells (Leech *et al.*, 1984 [↗](#), Su *et al.*, 1995 [↗](#), Smith *et al.*, 1995 [↗](#), Baruch *et al.*, 1995 [↗](#), Rask *et al.*, 2010 [↗](#)). *Var* genes are expressed in a mutually exclusive pattern, resulting in each parasite expressing only one *var* gene, and therefore one PfEMP1 protein, at a time (Scherf *et al.*, 1998 [↗](#)). Due to the exposure of PfEMP1 proteins to the host immune system, switching expression between the approximately 60 *var* genes in the genome is an effective immune evasion strategy, which can result in selection and dominance of parasites expressing particular *var* genes within each host (Smith *et al.*, 1995 [↗](#)).

Despite their sequence polymorphism, *var* genes could be classified into four categories (A, B, C, and E) according to their chromosomal location, transcriptional direction, type of 5'-upstream sequence (UPSA-E), and encoded protein domains with associated binding phenotype (Figure 1 [↗](#)) (Lavstsen *et al.*, 2003 [↗](#), Kraemer & Smith, 2003 [↗](#), Kyes *et al.*, 2007 [↗](#), Rask *et al.*, 2010 [↗](#)). PfEMP1 proteins have up to 10 extracellular domains, with the N-terminal domains forming a semi-conserved head structure complex typically containing the N-terminal segment (NTS), a Duffy binding-like domain of class  $\alpha$  (DBL $\alpha$ ) coupled to a cysteine-rich interdomain region (CIDR). C-terminally to this head structure, PfEMP1 proteins exhibit a varying but semi-ordered composition of additional DBL and CIDR domains of different subtypes (Figure 1c [↗](#)). The PfEMP1 family divides into three main groups based on the receptor specificity of the N-terminal CIDR domain: (i) PfEMP1 proteins with CIDR $\alpha$ 1 domains bind endothelial protein C receptor (EPCR), while (ii) PfEMP1 proteins with CIDR $\alpha$ 2–6 domains bind CD36 and (iii) the atypical VAR2CSA PfEMP1 proteins bind placental chondroitin sulphate A (CSA) (Salanti *et al.*, 2004 [↗](#)). In addition to these, a

subset of PfEMP1 proteins have N-terminal CIDR $\beta$ /y/8 domains of unknown function. This functional diversification correlates with the genetic organization of the *var* genes. Thus, UP5A *var* genes encode PfEMP1 proteins with domain sub-variants NTSA-DBLa1-CIDRa1/ $\beta$ /y/8, whereas UP5B and UP5C *var* genes encode PfEMP1 proteins with NT5B-DBLa0-CIDRa2–6. One exception to this rule is the B/A chimeric *var* genes, which encode NT5B-DBLa2-CIDRa1 domains. The different receptor binding specificities are associated with different clinical outcomes of infection. Pregnancy-associated malaria is linked to parasites expressing VAR2CSA, whereas parasites expressing EPCR-binding PfEMP1 are linked to severe malaria and parasites expressing CD36-binding PfEMP1 are linked to uncomplicated malaria (Turner *et al.*, 2013 [↗](#), Lavstsen *et al.*, 2012 [↗](#), Avril *et al.*, 2012 [↗](#), Claessens *et al.*, 2012 [↗](#), Tonkin-Hill *et al.*, 2018 [↗](#), Wichers *et al.*, 2021 [↗](#)). The clinical relevance of PfEMP1 proteins with unknown binding phenotypes of the N-terminal head structure and C-terminal PfEMP1 domains is largely unknown, albeit specific interactions with endothelial receptors and plasma proteins have been described (Tuikue Ndam *et al.*, 2017 [↗](#), Quintana *et al.*, 2019 [↗](#), Stevenson *et al.*, 2015 [↗](#)). Each parasite genome carries a similar repertoire of *var* genes, which in addition to the described variants include a highly conserved *var1* variant of either type 3D7 or IT, which in most genomes occurs with a truncated or absent exon 2. Also, most genomes carry the unusually small and highly conserved *var3* genes, of unknown function (Figure 1c [↗](#)) (Otto *et al.*, 2019 [↗](#)).

Comprehensive characterisation and quantification of *var* gene expression in field samples have been complicated by biological and technical challenges. The extreme polymorphism of *var* genes precludes a reference *var* sequence. *Var* genes can be lowly expressed or not expressed at all, contain repetitive domains and can have large duplications (Otto *et al.*, 2019 [↗](#)). Consequently, most studies relating *var* gene expression to severe malaria have relied on primers with restricted coverage of the *var* family, use of laboratory-adapted parasite strains or have predicted the downstream sequence from DBLa domains (Sahu *et al.*, 2021 [↗](#), Storm *et al.*, 2019 [↗](#), Shabani *et al.*, 2017 [↗](#), Mkumbaye *et al.*, 2017 [↗](#), Kessler *et al.*, 2017 [↗](#), Bernabeu *et al.*, 2016 [↗](#), Jespersen *et al.*, 2016 [↗](#), Lavstsen *et al.*, 2012 [↗](#)). This has resulted in incomplete *var* gene expression quantification and the inability to elucidate specific or detect atypical *var* sequences. RNA-sequencing has the potential to overcome these limitations and provide a better link between *var* expression and PfEMP1 phenotype in *in vitro* assays, co-expression with other genes or gene families and epigenetics. While approaches for *var* assembly and quantification based on RNA-sequencing have recently been proposed (Wichers *et al.*, 2021 [↗](#); Stucke *et al.*, 2021; Andrade *et al.*, 2020 [↗](#); Tonkin-Hill *et al.*, 2018 [↗](#), Duffy *et al.*, 2016), these still produce inadequate assembly of the biologically important N-terminal domain region, have a relatively high number of misassemblies and do not provide an adequate solution for handling the conserved *var* variants (Table S1).

*Plasmodium* parasites from human blood samples are often adapted to or expanded through *in vitro* culture to provide sufficient parasites for subsequent investigation of parasite biology and phenotype (Brown & Guler, 2020 [↗](#)). This is also the case for several studies assessing the PfEMP1 phenotype of parasites isolated from malaria-infected donors (Pickford *et al.*, 2021 [↗](#), Joste *et al.*, 2020 [↗](#), Storm *et al.*, 2019 [↗](#), Tuikue Ndam *et al.*, 2017 [↗](#), Bruske *et al.*, 2016 [↗](#), Claessens *et al.*, 2012 [↗](#), Lavstsen *et al.*, 2005 [↗](#), Jensen *et al.*, 2004 [↗](#), Kirchgatter & Portillo Hdél, 2002 [↗](#), Dimonte *et al.*, 2016 [↗](#), Hoo *et al.*, 2019 [↗](#)). However, *in vitro* conditions are considerably different to those found *in vivo*, for example in terms of different nutrient availability and lack of a host immune response (Brown & Guler, 2020 [↗](#)). Previous studies found inconsistent results in terms of whether *var* gene expression is impacted by culture and, if so, which *var* groups were the most affected (Zhang *et al.*, 2011 [↗](#), Peters *et al.*, 2007 [↗](#)). Similar challenges apply to the understanding of changes in *P. falciparum* non-polymorphic core genes in culture, with the focus previously being on long-term laboratory adapted parasites (Claessens *et al.*, 2017 [↗](#), Mackinnon *et al.*, 2009 [↗](#)). Consequently, direct interpretation of a short-term cultured parasite's transcriptome remains a challenge. It is fundamental to understand *var* genes in context with the parasite's core



**Figure 1**

### Summary of the *var* chromosomal location, *var* gene, PfEMP1 protein structure, and PfEMP1 binding phenotypes.

**a)** Chromosomal position and transcriptional direction (indicated by arrows) of the different *var* gene groups, designated by the respective type of upstream sequence (Kraemer and Smith et al., 2003, Lavstsen et al., 2003). **b)** Structure of the *var* gene which encodes the PfEMP1 protein. The *var* gene is composed of two exons, the first, around 3–9.4 kb, encodes the highly variable extracellular region and the transmembrane region (TM) of PfEMP1. Exon 2 is shorter with about 1.2 kb and encodes a semi-conserved intracellular region (acidic terminal segment, ATS). The PfEMP1 protein is composed of an N-terminal segment (NTS), followed by a variable number of Duffy binding-like (DBL) domains and cysteine-rich interdomain regions (CIDR) (Rask et al., 2010). **c)** Summary of PfEMP1 proteins encoded in the parasite genome, their composition of domain subtypes and associated N-terminal binding phenotype. Group A and some B proteins have an EPCR-binding phenotype; the vast majority of group B and C PfEMP1 proteins bind to CD36. Group A proteins also include those that bind a yet unknown receptor, as well as VAR1 and VAR3 variants with unknown function and binding phenotype. VAR2CSA (group E) binds placental CSA.

transcriptome. This could provide insights into *var* gene regulation and phenomena such as the proposed lower level of *var* gene expression in asymptomatic individuals (Almelli *et al.*, 2014 [↗](#), Andrade *et al.*, 2020 [↗](#)).


Here we present an improved method for assembly, characterization, and quantification of *var* gene expression from RNA-sequencing data. This new approach overcomes previous limitations and outperforms current methods, enabling a much greater understanding of the *var* transcriptome. We demonstrate the power of this new approach by evaluating changes in *var* gene expression of paired samples from clinical isolates of *P. falciparum* during their early transition to *in vitro* culture, across several generations. The use of paired samples, which are genetically identical and hence have the same *var* gene repertoire, allows validation of assembled transcripts and direct comparisons of expression. We complement this with a comparison of changes which occur in the non-polymorphic core transcriptome over the same transition into culture. We find a background of modest changes in *var* gene expression with unpredictable patterns of *var* gene switching, favouring an apparent convergence towards *var2csa* expression. More extensive changes were observed in the core transcriptome during the first cycle of culture, suggestive of a parasite stress response.

## Results

To extend our ability to characterise *var* gene expression profiles and changes over time in clinical *P. falciparum* isolates, we set out to improve current assembly methods. Previous methods for assembling *var* transcripts have focussed on assembling whole transcripts (Tonkin-Hill *et al.*, 2018 [↗](#), Wichers *et al.*, 2021 [↗](#), Guillochon *et al.*, 2022 [↗](#), Andrade *et al.*, 2020 [↗](#)). However, due to the diversity within PfEMP1 domains, their associations with disease severity and the fact different domain types are not inherited together, a method focussing on domain assembly first was developed. In addition, a novel whole transcript approach, using a different *de novo* assembler, was developed and their performance compared to the method of Wichers *et al.* (hereafter termed “original approach”, **Figure 2** [↗](#)) (Wichers *et al.*, 2021 [↗](#)). The new approaches made use of the MalariaGEN *P. falciparum* dataset, which led to the identification of additional multi-mapping non-core reads (a median of 3,955 reads per sample) prior to *var* transcript assembly (MalariaGen *et al.*, 2021). We incorporated read error correction and improved large scaffold construction with fewer misassemblies (see Methods). We then applied this pipeline to paired *ex vivo* and short-term *in vitro* cultured parasites to enhance our understanding of the impact of short-term culturing on the *var* transcriptome (**Figure 3** [↗](#)). The *var* transcriptome was assessed at several complementary levels: first, changes in the dominantly expressed *var* gene and the homogeneity of the *var* expression profile in paired samples were investigated; second, changes in *var* domain expression through culture were assessed; and third, *var* group and global *var* gene expression changes were evaluated. All these analyses on *var* expression were accompanied by analysis of the core transcriptome at the transition to short-term culture.

## Improving *var* transcript assembly, annotation and quantification

A laboratory and a clinical dataset were used to assess the performance of the different *var* assembly pipelines (**Figure 2** [↗](#)). The laboratory dataset was a *P. falciparum* 3D7 time course RNA-sequencing dataset (European nucleotide archive (ENA): PRJEB31535) (Wichers *et al.*, 2019 [↗](#)). The clinical dataset contained samples from 32 adult malaria patients, hospitalised in Hamburg,




**Figure 2**

### Overview of novel computational pipelines for assembling *var* transcripts.

The original approach (green) used SoapDeNovo-Trans (k=71) to perform whole *var* transcript assembly. The whole transcript approach (blue) focused on assembling whole *var* transcripts from the non-core reads using rnaSPAdes (k = 71). Contigs were then joined into longer transcripts using SSPACE. The domain approach (orange) assembled *var* domains first and then joined the domains into whole transcripts. Domains were assembled separately using three different *de novo* assemblers (SoapDeNovo2, Oases and rnaSPAdes). Next, a reference of assembled domains was composed and cd-hit (at sequence identity = 99%) was used to remove redundant sequences. Cap3 was used to merge and extend domain assemblies. Finally, SSPACE was used to join domains together. HMM models built on the [Rask et al., 2010](#) dataset were used to annotate the assembled transcripts ([Rask et al., 2010](#)). The most significant alignment was taken as the best annotation for each region of the assembled transcript (significance <= 1e-5) identified using cath-resolve-hits0. Transcripts < 500nt were removed. A *var* transcript was selected if it contained at least one significantly annotated domain (in exon 1). *Var* transcripts that encoded only the more conserved exon 2 (ATS domain) were discarded. The three pipelines were run on the 32 malaria patient *ex vivo* samples from [Wichers et al., 2021](#) ([Wichers et al., 2021](#)).





**Figure 3**

### Summary of analyses of *var* and core gene transcriptome changes in paired *ex vivo* and short-term *in vitro* cultured parasites.

From a total of 13 parasite isolates, the *ex vivo* samples (Wichers *et al.*, 2021 [\[1\]](#)) and the corresponding *in vitro*-cultured parasites of the first (n=13), second (n=10) and third (n=1) replication cycle were analysed by RNA sequencing. The expression of non-polymorphic core genes and polymorphic *var* genes was determined in different analysis streams: (1) Non-polymorphic core gene reads were mapped to the 3D7 reference genome, expression was quantified using HTSeq and differential expression analysis performed (orange); (2) Non-core reads were identified, whole transcripts were assembled with rnaSPAdes, expression of both *var* transcripts (red) and domains (light green) was quantified, and *var* domain differential expression analysis was performed. “Per patient analysis” (yellow) represents combining all assembled *var* transcripts for samples originating from the same *ex vivo* sample only. For each conserved *var* gene (*var1-3D7*, *var1-IT*, *var2csa* and *var3*) all significantly assembled conserved *var* transcripts were identified and put into a combined reference (pink). The normalised counts for each conserved gene were summed. Non-core reads were mapped to this and DESeq2 normalisation performed. *Var* type (group A vs group B and C) expression (purple) was quantified using the DBLa and NTS assembled sequences and differences across generations were assessed. Total *var* gene expression (turquoise) was quantified by assembling and quantifying the coverage over the highly conserved LARSFADIG motif, with the performance of assembly using Trinity and rnaSPAdes assessed. DBLa-tag data was used to confirm the results of the dominant *var* gene expression analysis and the *var* type analysis (dark green). *Var* expression homogeneity (VEH) was analysed at the patient level ( $\alpha$  diversity curves). All differential expression analyses were performed using DESeq2. To ensure a fair comparison of samples, which may contain different proportions of life cycle stages, the performance of two different *in silico* approaches was evaluated by counting Giemsa-stained thin blood smears (blue).

Germany (National Center for Biotechnology Information (NCBI) BioProject ID: PRJNA679547). Fifteen were malaria naïve and 17 were previously exposed to malaria. Eight of the malaria naïve patients went on to develop severe malaria and 24 had non-severe malaria (Wichers *et al.*, 2021 [DOI](#)).

Our i) new whole transcript approach, ii) domain assembly approach, and iii) modified version of the original approach (see material and methods) were first applied to a *P. falciparum* 3D7 time course RNA-sequencing dataset to benchmark their performance (Wichers *et al.*, 2019 [DOI](#)) (**Figure 2** [DOI](#) – Figure supplement 1). The whole transcript approach performed best, achieving near perfect alignment scores for the dominantly expressed *var* gene (**Figure 2** [DOI](#) – Figure supplement 1a). The domain and the original approach produced shorter contigs and required more contigs to assemble the *var* transcripts at the 8 and 16 hour post-invasion time points, when *var* gene expression is maximal (**Figure 2** [DOI](#) – Figure supplement 1c, f, g and h). However, we found high accuracies (> 0.95) across all approaches, meaning the sequences we assembled were correct (**Figure 2** [DOI](#) – Figure supplement 1b). The whole transcript approach also performed the best when assembling the lower expressed *var* genes (**Figure 2** [DOI](#) – Figure supplement 1e) and produced the fewest *var* chimeras compared to the original approach on *P. falciparum* 3D7. Fourteen misassemblies were observed with the whole transcript approach compared to 19 with the original approach (Table S2). This reduction in misassemblies was particularly apparent in the ring-stage samples.

Next, the assembled transcripts produced from the original approach of Wichers *et al.*, 2021 [DOI](#) were compared to those produced from our new whole transcript and domain assembly approaches for *ex vivo* samples from German travellers. Summary statistics are shown in **Table 1** [DOI](#). The whole transcript approach produced the fewest transcripts, but of greater length than the domain approach and the original approach (**Figure 2** [DOI](#) – Figure supplement 2). The whole transcript approach also returned the largest N50 score (more than doubling the N50 of the original approach), which means that it was the most contiguous assembly produced. Remarkably, with the new whole transcript method, we observed a significant decrease (2 vs 336) in clearly misassembled transcripts with, for example, an N-terminal domain at an internal position.

When genome sequencing is not available, concordance of different *var* profiling approaches can support the validation of an approach. Here, the same methods used in the original analysis were applied for quantifying the expression of the assembled *var* transcripts and domains. This suggests any concordance in expression estimates likely reflects concordance at the domain annotation level. The original approach and the new whole transcript approach gave similar results for domain expression in each sample with greater correlation in results observed between the highly expressed domains (**Figure 2** [DOI](#) – Figure supplement 3). As expected, comparable results were also seen for the differentially expressed transcripts identified in the original analysis between the naïve vs pre-exposed and severe vs non-severe comparisons, respectively (**Figure 2** [DOI](#) – Figure supplement 4).

Overall, the new whole transcript approach performed the best on the laboratory 3D7 dataset (ENA: PRJEB31535) (Wichers *et al.*, 2019 [DOI](#)), had the greatest N50, the longest *var* transcripts and produced concordant results with the original analysis on the clinical *ex vivo* samples (NCBI: PRJNA679547) (Wichers *et al.*, 2021 [DOI](#)). Therefore, it was selected for all subsequent analyses unless specified otherwise.



	Number of contigs ≥500nts	Maximum length (nt)	Average contig length (nt)	N50	Number of misassemblies
Original approach	6,441	10,412	1,621	2,302	336
Domain approach	4,691	5,003	954	1,088	NA**
Whole transcript approach	3,011	12,586	2,771	5,381	2

**Table 1**

**Statistics for the different approaches used to assemble the *var* transcripts.**

*Var* assembly approaches were applied to malaria patient *ex vivo* samples (n=32) from (Wichers *et al.*, 2021 [link](#)) and statistics determined. Given are the total number of assembled *var* transcripts longer than 500 nt containing at least one significantly annotated *var* domain, the maximum length of the longest assembled *var* transcript in nucleotides and the N50 value, respectively. The N50 is defined as the sequence length of the shortest *var* contig, with all *var* contigs greater than or equal to this length together accounting for 50% of the total length of concatenated *var* transcript assemblies. Misassemblies represents the number of misassemblies for each approach. \*\*Number of misassemblies were not determined for the domain approach due to its poor performance in other metrics.

## Establishing characterisation of *var* transcripts from *ex vivo* and *in vitro* samples

Of the 32 clinical isolates of *P. falciparum* from the German traveller dataset, 13 underwent one replication cycle of *in vitro* culture, 10 of these underwent a second generation and one underwent a third generation (Table 2). Most (9/13, 69%) isolates entering culture had a single MSP1 genotype, indicative of monoclonal infections. All samples were sequenced with a high read depth, although the *ex vivo* samples had a greater read depth than the *in vitro* samples (Table 2). Figure 3 shows a summary of the analysis performed.

To account for differences in parasite developmental stage within each sample, which are known to impact gene expression levels (Bozdech *et al.*, 2003), the proportions of life cycle stages were estimated using the mixture model approach of the original analysis (Tonkin-Hill *et al.*, 2018, Wichers *et al.*, 2021). As a complementary approach, single cell differential composition analysis (SCDC) with the Malaria Cell Atlas as a reference was also used to determine parasite age (Dong *et al.*, 2021, Howick *et al.*, 2019). SCDC and the mixture model approaches produced concordant estimates that most parasites were at ring stage in all *ex vivo* and *in vitro* samples (Figure 3 – Figure supplement 1a,b). Whilst there was no significant difference in ring stage proportions across the generations, we observed a slight increase in parasite age in the cultured samples. Overall, there were more rings and early trophozoites in the *ex vivo* samples compared to the cultured parasite samples and an increase of late trophozoite, schizont and gametocyte proportions during the culturing process (Figure 3 – Figure supplement 1c). The estimates produced from the mixture model approach showed high concordance with those observed by counting Giemsa-stained blood smears (Figure 3 – Figure supplement 1d). Due to the potential confounding effect of differences in stage distribution on gene expression, we adjusted for developmental stage determined by the mixture model in all subsequent analyses.

Our new approach was applied to RNA-sequencing samples of *ex vivo* and short-term *in vitro* cultured parasites from German travellers (Wichers *et al.*, 2021). Table S3 shows the assembled *var* transcripts on a per sample basis. Interestingly, we observed SSPACE did not provide improvement in terms of extending *var* assembled contigs in 9/37 samples. We observed a significant increase in the number of assembled *var* transcripts in generation 2 parasites compared to paired generation 1 parasites ( $p_{\text{adj}} = 0.04$ , paired Wilcoxon test). We observed no significant differences in the length of the assembled *var* transcripts across the generations. Three different filtering approaches were applied in comparison to maximise the likelihood that correct assemblies were taken forward for further analysis and to avoid the overinterpretation of lowly expressed partial *var* transcripts (Table S4). Filtering for *var* transcripts at least 1500nt long and containing at least 3 significantly annotated *var* domains was the least restrictive, while the other approaches required the presence of a DBLa domain within the transcript. All three filtering approaches generated the same maximum length *var* transcript and similar N50 values. This suggests minimal differences in the three filtering approaches, whilst highlighting the importance of filtering assembled *var* transcripts.

In the original approach of Wichers *et al.*, 2021, the non-core reads of each sample used for *var* assembly were mapped against a pooled reference of assembled *var* transcripts from all samples, as a preliminary step towards differential *var* transcript expression analysis. This approach returned a small number of *var* transcripts which were expressed across multiple patient samples (Figure 3 – Figure supplement 2a). As genome sequencing was not available, it was not possible to know whether there was truly overlap in *var* genomic repertoires of the different patient samples, but substantial overlap was not expected. Stricter mapping approaches (for example, excluding transcripts shorter than 1500nt) changed the resulting *var* expression profiles and produced more realistic scenarios where similar *var* expression profiles were generated across paired samples, whilst there was decreasing overlap across different patient samples (Figure 3

		Generation			
		<i>Ex vivo</i> (n=32)	1 (n=13)	2 (n=10)	3 (n=1)
Malaria exposure (n)	Naïve	15	6	4	1
	Previously exposed	17	7	6	0
Malaria severity (n)	Severe	8	3	1	0
	Non-severe	24	10	9	1
Number of MSP1 genotypes (number of samples)	1	22	9	7	1
	2	4	0	0	0
	3	5	3	0	0
	4	1	1	0	0
Number of <i>P. falciparum</i> PE* reads (non-var) (median, IQR) (million of reads)		34.6 (27.0–36.5)	17.1 (12.9–18.0)	17.2 (12.9–19.1)	15.1
Number of non-core <i>P. falciparum</i> PE* reads (median, IQR) (million of reads)		5.05 (3.62–6.60)	1.16 (1.07–1.40)	1.29 (1.04–1.58)	0.91
Number of assembled <i>var</i> contigs in a sample (≥500nts) (whole transcript approach) (median, IQR)		53 (44–84)	61 (38–76)	71.5 (48.25–79.5)	75
Number of assembled <i>var</i> contigs in a sample (≥1,500nts and 3 sig. domain annotations) (whole transcript approach) (median, IQR)		20 (7–31)	15.5 (10–26)	15 (10.25–23.75)	18

**Table 2**

### Summary of the clinical dataset used to analyze the impact of parasite culturing on gene expression.

RNA-sequencing was performed on 32 malaria infected German traveler samples (Wichers *et al.*, 2021 [DOI](#)). The 32 *ex vivo* samples were used to compare the performance of the *var* assembly approaches. Parasites from 13 of these *ex vivo* samples underwent one cycle of *in vitro* replication, 10 parasite samples were also subjected to a second cycle of replication *in vitro*, and a single parasite isolate was also analyzed after a third cycle of replication. For the *ex vivo* vs short-term *in vitro* cultivation analysis only paired samples were used. The number of assembled *var* contigs represents results per sample using the whole transcript approach, and shows either the number of assembled *var* contigs significantly annotated as *var* gene and > =500nt in length, or the number of assembled *var* transcripts identified with a length >= 1500nt and containing at least 3 significantly annotated *var* domains. \*PE; paired-end reads.


– Figure supplement 2b,c). Given this limitation, we used the paired samples to analyse *var* gene expression at an individual subject level, where we confirmed the MSP1 genotypes and alleles were still present after short-term *in vitro* cultivation. The per patient approach showed consistent expression of *var* transcripts within samples from each patient but no overlap of *var* expression profiles across different patients (Figure 3 – Figure supplement 2d). Taken together, the per patient approach was better suited for assessing *var* transcriptional changes in longitudinal samples. However, it has been hypothesised that more conserved *var* genes in field isolates increase parasite fitness during chronic infections, necessitating the need to correctly identify them (Dimonte *et al.*, 2020, Otto *et al.*, 2019). Accordingly, further work is needed to optimise the pooled sample approach to identify truly conserved *var* transcripts across different parasite isolates in cross-sectional studies.

## Longitudinal analysis of *var* transcriptome from *ex vivo* to *in vitro* samples

To assess the changes in the *var* transcriptome induced by parasite culturing, we performed a series of analyses, all of which addressed different aspects: (i) changes in individual *var* gene expression pattern and *var* expression homogeneity (“per patient analysis”), (ii) changes in the expression of *var* variants conserved between strains, (iii) changes in the expression of PfEMP1 domains, (iv) changes in expression at the *var* group level, and (v) at the overall *var* expression level. We validated our results using the DBLa-tag approach and complemented the *var* –specific analysis by also examining changes in the core transcriptome.

To investigate whether dominant *var* gene expression changes through *in vitro* culture, rank analysis of *var* transcript expression was performed (Figure 4 – Figure supplement 1). In most cases a single dominant *var* transcript was detected. The dominant *var* gene did not change in most patient samples and the ranking of *var* gene expression remained similar. However, we observed a change in the dominant *var* gene being expressed through culture in isolates from three of 13 (23%) patients (#6, #17 and #26). Changes in the dominant *var* gene expression were also observed in the DBLa-tag data for these patients (described below). In parasites from three additional patients, #1, #7 and #14, the top expressed *var* gene remained the same, however we observed a change in the ranking of other highly expressed *var* genes in the cultured samples compared to the *ex vivo* sample. Interestingly, in patient #26 we observed a switch from a dominant group A *var* gene to a group B and C *var* gene. This finding was also observed in the DBLa-tag analysis (results below). A similar finding was seen in patient #7. In the *ex vivo* sample, the second most expressed *var* transcript was a group A transcript. However, in the cultured samples expression of this transcript was reduced and we observed an increase in the expression of group B and C *var* transcripts. A similar pattern was observed in the DBLa-tag analysis for patient #7, whereby the expression of a group A transcript was reduced during the first cycle of cultivation. Overall, the data suggest that some patient samples underwent a larger *var* transcriptional change when cultured compared to the other patient samples and that culturing parasites can lead to an unpredictable *var* transcriptional change.

In line with these results, *var* expression homogeneity (VEH) on a per patient basis showed in some patients a clear change, with the *ex vivo* sample diversity curve distinct from those of *in vitro* generation 1 and generation 2 samples (patients #1, #2, #4) (Figure 4 – Figure supplement 2). Similarly, in other patient samples, we observed a clear difference in the curves of *ex vivo* and generation 1 samples (patient #25 and #26, both from first-time infected severe malaria patients). Some of these samples (#1 and #26, both from first-time infected severe malaria patients) also showed changes in their dominant *var* gene expression during culture, taken together indicating much greater *var* transcriptional changes *in vitro* compared to the other samples.



**Figure 4**

### Rank *var* gene expression analysis.

For each patient, the paired *ex vivo* (n=13) and *in vitro* samples (generation 1: n=13, generation 2: n=10, generation 3: n=1) were analysed. The assembled *var* transcripts with at least 1500nt and containing 3 significantly annotated *var* domains across all the generations for a patient were combined into a reference, redundancy was removed using cd-hit (at sequence identity = 99%), and expression was quantified using Salmon. *Var* transcript expression was ranked. Plots show the top 10 *var* gene expression rankings for each patient and their *ex vivo* and short-term *in vitro* cultured parasite samples. Group A *var* transcripts (red), group B or C *var* transcripts (blue), group E *var* transcripts (green) and transcripts of unknown *var* group (orange).

## Expression of conserved *var* gene variants through short-term *in vitro* culture

Due to the relatively high level of conservation observed in *var1*, *var2csa* and *var3*, they do not present with the same limitations as regular *var* genes. Therefore, changes in their expression through short-term culture was investigated across all samples together. We observed no significant differences in the expression of conserved *var* gene variants, *var1-IT* ( $p_{\text{adj}} = 0.61$ , paired Wilcoxon test), *var1-3D7* ( $p_{\text{adj}} = 0.93$ , paired Wilcoxon test) and *var2csa* ( $p_{\text{adj}} = 0.54$ , paired Wilcoxon test) between paired *ex vivo* and generation 1 parasites, but *var2csa* was significantly differentially expressed between generation 1 and generation 2 parasites ( $p_{\text{adj}} = 0.029$ , paired Wilcoxon test) (**Figure 4** – Figure supplement 3). However, *var2csa* expression previously appeared to have decreased in some paired samples during the first cycle of cultivation (**Figure 4** – Figure supplement 3).

## Differential expression of *var* domains from *ex vivo* to *in vitro* samples


There is overlap in PfEMP1 domain subtypes of different parasite isolates which can be associated with *var* gene groups and receptor binding phenotypes. This allows performing differential expression analysis on the level of encoded PfEMP1 domain subtypes, as done in previous studies (Tonkin-Hill *et al.*, 2018, Wichers *et al.*, 2021). PCA on *var* domain expression (**Figure 5a**) showed some patients' *ex vivo* samples clustering away from their respective generation 1 sample (patient #1, #2, #4, #12, #17, #25), again indicating a greater *var* transcriptional change relative to the other samples during the first cycle of cultivation. However, in the pooled comparison of the generation 1 vs *ex vivo* of all isolates, a single domain was significantly differentially expressed, CIDRa2.5 associated with B-type PfEMP1 proteins and CD36-binding (**Figure 5b**). In the generation 2 vs *ex vivo* comparison, there were no domains significantly differentially expressed, however we observed large  $\log_2\text{FC}$  values in similar domains to those changing most in the *ex vivo* vs generation 1 comparison (**Figure 5c**). No differentially expressed domains were found in the generation 1 vs generation 2 comparison. These results suggest individual changes in *var* expression are not reflected in the pooled analysis and the per patient approach is more suitable.

## *Var* group expression analysis

A previous study found group A *var* genes to have a rapid transcriptional decline in culture compared to group B *var* genes, however another study found a decrease in both group A and group B *var* genes in culture (Zhang *et al.*, 2011, Peters *et al.*, 2007). These studies were limited as the *var* type was determined by analysing the sequence diversity of DBLa domains, and by quantitative PCR (qPCR) methodology which restricts analysis to quantification of known/conserved sequences. Due to these results, the expression of group A *var* genes vs. group B and C *var* genes was investigated using a paired analysis on all the DBLa (DBLa1 vs DBLa0 and DBLa2) and NTS (NTSA vs NTSB) sequences assembled from *ex vivo* samples and across multiple generations in culture. A linear model was created with group A expression as the response variable, the generation and life cycle stage as independent variables and the patient information included as a random effect. The same was performed using group B and C expression levels.

In both approaches, DBLa and NTS, we found no significant changes in total group A or group B and C *var* gene expression levels (**Figure 6**). We observed high levels of group B and C *var* gene expression compared to group A in all patients, both in the *ex vivo* samples and the *in vitro*





**Figure 5**

### Var domain transcriptome analysis through short-term *in vitro* culture.

Var transcripts for paired *ex vivo* (n=13), generation 1 (n=13), generation 2 (n=10) and generation 3 (n=1) were *de novo* assembled using the whole transcript approach. Var transcripts were filtered for those  $\geq 1500$ nt in length and containing at least 3 significantly annotated var domains. Transcripts were annotated using HMM models built on the Rask et al., 2010 dataset (Rask et al., 2010). When annotating the whole transcript, the most significant alignment was taken as the best annotation for each region of the assembled transcript (e-value cut off  $1e-5$ ). Multiple annotations were allowed on the transcript if they were not overlapping, determined using cath-resolve-hits. Var domain expression was quantified using FeatureCounts and the domain counts aggregated **a**) PCA plot of log<sub>2</sub> normalized read counts (adjusted for life cycle stage, derived from the mixture model approach). Points are coloured by their generation (*ex vivo*; purple, generation 1; red, generation 2; green and generation 3; blue) and labelled by their patient identity **b**) Volcano plot showing extent and significance of up-or down-regulation of var domain expression in *ex vivo* (n=13) compared with paired generation 1 cultured parasites (n=13) (red and blue,  $P < 0.05$  after Benjamini-Hochberg adjustment for FDR; red and green, absolute log<sub>2</sub> fold change log<sub>2</sub>FC in expression  $\geq 2$ ). Domains with a log<sub>2</sub>FC  $\geq 2$  represent those upregulated in generation 1 parasites. Domains with a log<sub>2</sub>FC  $\leq -2$  represent those downregulated in generation 1 parasites. **c**) Volcano plot showing extent and significance of up-or down-regulation of var domain expression in *ex vivo* (n=10) compared with paired generation 2 cultured parasites (n=10) (green, absolute log<sub>2</sub> fold change log<sub>2</sub>FC in expression  $\geq 2$ ). Domains with a log<sub>2</sub>FC  $\geq 2$  represent those upregulated in generation 2 parasites. Domains with a log<sub>2</sub>FC  $\leq -2$  represent those downregulated in generation 2 parasites. Differential expression analysis was performed using DESeq2 (adjusted for life cycle stage, derived from the mixture model approach).

samples. In some patients we observed a decrease in group A *var* genes from *ex vivo* to generation 1 (patients #1, #2, #5, #6, #9, #12, #17, #26) (**Figure 6a** [↗](#)), however in all but four patients (patient #1, #2, #5, #6) the levels of group B and C *var* genes remained consistently high from *ex vivo* to generation 1 (**Figure 6b** [↗](#)). Interestingly, patients #6 and #17 also had a change in the dominant *var* gene expression through culture. Taken together with the preceding results, it appears that observed differences in *var* transcript expression occurring with transition to short-term culture are not due to modulation of recognised *var* classes, but due to differences in expression of particular *var* transcripts.


## Quantification of total *var* gene expression

We observed a trend of decreasing total *var* gene expression between generations irrespective of the assembler used in the analysis (**Figure 6** [↗](#) – Figure supplement 1). A similar trend is seen with the LARSFADIG count, which is commonly used as a proxy for the number of different *var* genes expressed (Otto *et al.*, 2019 [↗](#)). A linear model was created (using only paired samples from *ex vivo* and generation 1) (Supplementary file 1) with proportion of total gene expression dedicated to *var* gene expression as the response variable, the generation and life cycle stage as independent variables and the patient information included as a random effect. This model showed no significant differences between generations, suggesting that differences observed in the raw data may be a consequence of small changes in developmental stage distribution in culture.

## Validation of *var* expression profiling by DBLα-tag sequencing

Deep sequencing of RT-PCR-amplified DBLα expressed sequence tags (ESTs) combined with prediction of the associated transcripts and their encoded domains using the Varia tool (Mackenzie *et al.*, 2022 [↗](#)) was performed to supplement the RNA-sequencing analysis. The raw Varia output file is given in Supplementary file 2. Overall, we found a high agreement between the detected DBLα-tag sequences and the *de novo* assembled *var* transcripts. A median of 96% (IQR: 93–100%) of all unique DBLα-tag sequences detected with >10 reads were found in the RNA-sequencing approach. This is a significant improvement on the original approach ( $p = 0.0077$ , paired Wilcoxon test), in which a median of 83% (IQR: 79–96%) was found (Wichers *et al.*, 2021 [↗](#)). To allow for a fair comparison of the >10 reads threshold used in the DBLα-tag approach, the upper 75<sup>th</sup> percentile of the RNA-sequencing-assembled DBLα domains were analysed. A median of 77.4% (IQR: 61–88%) of the upper 75<sup>th</sup> percentile of the assembled DBLα domains were found in the DBLα-tag approach. This is a lower median percentage than the median of 81.3% (IQR: 73–98%) found in the original analysis ( $p = 0.28$ , paired Wilcoxon test) and suggests the new assembly approach is better at capturing all expressed DBLα domains.

The new whole transcript assembly approach also had high consistency with the domain annotations predicted from Varia. Varia predicts *var* sequences and domain annotations based on short sequence tags, using a database of previously defined *var* sequences and annotations (Mackenzie *et al.*, 2022 [↗](#)). A median of 85% of the DBLα annotations and 73% of the DBLα-CIDR domain annotations, respectively, identified using the DBLα-tag approach were found in the RNA sequencing approach. This further confirms the performance of the whole transcript approach and it was not restricted by the pooled approach of the original analysis. We also observed consistent results with the per patient analysis, in terms of changes in the dominant *var* gene expression (described above) (Supplementary file 2). In line with the RNA-sequencing data, the



**Figure 6.**

### Var group expression analysis through short-term *in vitro* culture.

The DBLa domain sequence for each transcript was determined and for each patient a reference of all assembled DBLa domains combined. Group A *var* genes possess DBLa1 domains, some group B encode DBLa2 domains and groups B and C encode DBLa0 domains. Domains were grouped by type and their expression summed. The relevant sample's non-core reads were mapped to this using Salmon and DBLa expression quantified. DESeq2 normalisation was performed, with patient identity and life cycle stage proportions included as covariates. A similar approach was repeated for NTS domains. Group A *var* genes encode NTSA compared to group B and C *var* genes which encode NTSB. Boxplots show log<sub>2</sub> normalised Salmon read counts for **a)** group A *var* gene expression through cultured generations assessed using the DBLa domain sequences, **b)** group B and C *var* gene expression through cultured generations assessed using the DBLa domain sequences, **c)** group A *var* gene expression through cultured generations assessed using the NTS domain sequences, and **d)** group B and C *var* gene expression through cultured generations assessed using the NTS domain sequences. Different coloured lines connect paired patient samples through the generations: *ex vivo* (n=13), generation 1 (n=13), generation 2 (n=10) and generation 3 (n=1). Axis shows different scaling.

DBL $\alpha$ -tag approach revealed no significant differences in Group A and Group B and C groups during short-term culture, further highlighting the agreement of both methods (**Figure 6** – Figure supplement 2).

## Differential expression analysis of the core transcriptome between *ex vivo* and *in vitro* samples

Given the modest changes in *var* gene expression repertoire upon culture we wanted to investigate the extent of any accompanying changes in the core parasite transcriptome. PCA was performed on core gene (*var*, *rif*, *stevor*, *surf* and rRNA genes removed) expression, adjusted for life cycle stage. We observed distinct clustering of *ex vivo*, generation 1, and generation 2 samples, with patient identity having much less influence (**Figure 7a**). There was also a change from the heterogeneity between the *ex vivo* samples to more uniform clustering of the generation 1 samples (**Figure 7a**), suggesting that during the first cycle of cultivation the core transcriptomes of different parasite isolates become more alike.

In total, 920 core genes (19% of the core transcriptome) were found to be differentially expressed after adjusting for life cycle stages using the mixture model approach between *ex vivo* and generation 1 samples (Supplementary file 3). The majority were upregulated, indicating a substantial transcriptional change during the first cycle of *in vitro* cultivation (**Figure 7b**). 74 genes were found to be upregulated in generation 2 when compared to the *ex vivo* samples, many with log<sub>2</sub>FC greater than those in the *ex vivo* vs generation 1 comparison (**Figure 7c**). No genes were found to be significantly differentially expressed between generation 1 and generation 2. However, five genes had a log<sub>2</sub>FC  $\geq 2$  and were all upregulated in generation 2 compared to generation 1. Interestingly, the gene with the greatest fold change, encoding ROM3 (PF3D7\_0828000), was also found to be significantly downregulated in generation 1 parasites in the *ex vivo* vs generation 1 analysis. The other four genes were also found to be non-significantly downregulated in generation 1 parasites in the *ex vivo* vs generation 1 analysis. This suggests changes in gene expression during the first cycle of cultivation are the greatest compared to the other cycles.

The most significantly upregulated genes (in terms of fold change) in generation 1 contained several small nuclear RNAs, splicesomal RNAs and non-coding RNAs (ncRNAs). 16 ncRNAs were found upregulated in generation 1, with several RNA-associated proteins having large fold changes (log<sub>2</sub>FC > 7). Significant gene ontology (GO) terms and Kyoto encyclopedia of genes and genomes (KEGG) pathways for the core genes upregulated in generation 1 included “entry into host”, “movement into host” and “cytoskeletal organisation” suggesting the parasites undergo a change in invasion efficiency, which is connected to the cytoskeleton, during their first cycle of *in vitro* cultivation (**Figure 7** – Figure supplement 1). We observed eight AP2 transcription factors upregulated in generation 1 (PF3D7\_0404100/AP2-SP2, PF3D7\_0604100/SIP2, PF3D7\_0611200/AP2-EXP2, PF3D7\_0613800, PF3D7\_0802100/AP2-LT, PF3D7\_1143100/AP2-O, PF3D7\_1239200, PF3D7\_1456000/AP2-HC) with no AP2 transcription factors found to be downregulated in generation 1. To confirm the core gene expression changes identified were not due to the increase in parasite age during culture, as indicated by upregulation of many schizont-related genes, core gene differential expression analysis was performed on paired *ex vivo* and generation 1 samples that contained no schizonts or gametocytes in generation 1. The same genes were identified as significantly differentially expressed with a Spearman’s rank correlation of 0.99 for the log<sub>2</sub>FC correlation between this restricted sample approach and those produced using all samples (**Figure 7** – Figure supplement 2).



## Cultured parasites as surrogates for assessing the *in vivo* core gene transcriptome

In the original analysis of *ex vivo* samples, hundreds of core genes were identified as significantly differentially expressed between pre-exposed and naïve malaria patients. We investigated whether these differences persisted after *in vitro* cultivation. We performed differential expression analysis comparing parasite isolates from naïve (n=6) vs pre-exposed (n=7) patients, first between their *ex vivo* samples, and then between the corresponding generation 1 samples. Interestingly, when using the *ex vivo* samples, we observed 206 core genes significantly upregulated in naïve patients compared to pre-exposed patients (**Figure 7** – Figure supplement 3a). Conversely, we observed no differentially expressed genes in the naïve vs pre-exposed analysis of the paired generation 1 samples (**Figure 7** – Figure supplement 3b). Taken together with the preceding findings, this suggests one cycle of cultivation shifts the core transcriptomes of parasites to be more alike each other, diminishing inferences about parasite biology *in vivo*.

**Table 3** provides an overview of the different levels of analysis performed, including their rationale, the methods used, the resulting findings, and their interpretation.

## Discussion

Multiple lines of evidence point to PfEMP1 as a major determinant of malaria pathogenesis, but previous approaches for characterising *var* expression profiles in field samples have limited *in vivo* studies of PfEMP1 function, regulation, and association with clinical symptoms (Tarr *et al.*, 2018, Lee *et al.*, 2018, Warimwe *et al.*, 2013, Rorick *et al.*, 2013, Zhang *et al.*, 2011, Taylor *et al.*, 2002). A more recent approach, based on RNA-sequencing, overcame many of the limitations imposed by the previous primer-based methods (Tonkin-Hill *et al.*, 2018, Wichers *et al.*, 2021). However, depending on the expression level and sequencing depth, *var* transcripts were found to be fragmented and only a partial reconstruction of the *var* transcriptome was achieved (Tonkin-Hill *et al.*, 2018, Wichers *et al.*, 2021, Andrade *et al.*, 2020, Guillochon *et al.*, 2022, Yamagishi *et al.*, 2014). The present study developed a novel approach for *var* gene assembly and quantification that overcomes many of these limitations.

Our new approach used the most geographically diverse reference of *var* gene sequences to date, which improved the identification of reads derived from *var* transcripts. This is crucial when analysing patient samples with low parasitaemia where *var* transcripts are hard to assemble due to their low abundance (Guillochon *et al.*, 2022). Our approach has wide utility due to stable performance on both laboratory-adapted and clinical samples. Concordance in the different *var* expression profiling approaches (RNA-sequencing and DBLα-tag) on *ex vivo* samples increased using the new approach by 13%, when compared to the original approach (96% in the whole transcript approach compared to 83% in Wichers *et al.*, 2021). This suggests the new approach provides a more accurate method for characterising *var* genes, especially in samples collected directly from patients. Ultimately, this will allow a deeper understanding of relationships between *var* gene expression and clinical manifestations of malaria.

Having a low number of long contigs is desirable in any *de novo* assembly. This reflects a continuous assembly, as opposed to a highly fragmented one where polymorphic and repeat regions could not be resolved (Lischer & Shimizu, 2017). An excessive number of contigs cannot be reasonably handled computationally and results from a high level of ambiguity in the assembly (Yang *et al.*, 2012). We observed a greater than 50% reduction in the number of contigs produced in our new approach, which also had a 21% increase in the maximum length of the assembled *var* transcripts, when compared to the original approach. It doubled the assembly



Analysis level	Analysis	Rationale	Method	Results	Interpretation
<b>var transcript</b>	Per patient expression ranking	Relative quantification of <i>var</i> transcripts over consecutive generations of parasites originating from the same patient to reveal <i>var</i> gene switching events	Combine assembled <i>var</i> transcripts for each patient into a reference and quantify expression, validated with DBLα-tag analysis	46% of the patient samples had a change in the dominant or top 3 highest expressed <i>var</i> gene	Modest changes in most samples, but unpredictable <i>var</i> gene switching during culture in some samples
	Per patient <i>var</i> expression homogeneity (VEH)	Determine the overall diversity of <i>var</i> gene expression (number of different variants expressed and their abundance) to assess impact of culturing on the overall <i>var</i> gene expression pattern	Comparison of diversity curves based on per patient quantification of the <i>var</i> transcriptome	39% of <i>ex vivo</i> samples diversity curves distinct from <i>in vitro</i> samples	Some patient samples underwent a much greater <i>var</i> transcriptional change compared to others
	Conserved <i>var</i> variants	Assessing and comparing the expression levels of strain-transcendent <i>var</i> gene variants ( <i>var1</i> , <i>var2csa</i> , <i>var3</i> ) between samples	Reference of all assembled transcripts for each conserved <i>var</i> gene and quantify expression	<i>var2csa</i> expression increases in 2nd <i>in vitro</i> generation	Parasites converge to <i>var2csa</i> during short-term <i>in vitro</i> culture
<b>var-encoded PfEMP1 domains</b>	Differential expression of PfEMP1 domains	Identification, quantification and comparison of expression levels of different <i>var</i> gene-encoded PfEMP1 domains associated with different disease manifestations	Pool all assembled <i>var</i> transcripts into a reference and quantify expression of each domain	46% of the <i>ex vivo</i> samples cluster away from their <i>in vitro</i> samples in PCA plots, distinct clustering by <i>in vitro</i> generation was not observed; CIDRa2.5 significantly differentially expressed between <i>ex vivo</i> and generation 1	Transition to culture results in modest modulation of particular <i>var</i> domains
<b>var group</b>	Expression of NTS (NTSA vs NTSB) and DBLα (DBLα1 vs DBLα0+ DBLα2)	Quantification and comparison of expression levels of different <i>var</i> gene groups (group A vs. group B and C)	Create a reference of all assembled DBLα and NTS domains for each patient and quantify expression. Validated with DBLα-tag analysis	No significant changes	No preferential up or down regulation of certain <i>var</i> groups during transition to culture
<b>Global var expression</b>	LARSFADIG coverage	Assessing the overall <i>var</i> gene expression level (excluding <i>var2csa</i> )	Assemble the LARSFADIG motif and map non-core reads to quantify coverage	Trend for decrease in global <i>var</i> expression during culture, but no significant changes	Subtle reduction in global <i>var</i> gene expression may reflect increase in parasite age during culture
<b>Core genes</b>	Differential gene expression (DGE)	Assessing the impact of cultivation on the parasite core gene transcriptome	Differential expression analysis of core genes ( <i>P. falciparum</i> 3D7 used as reference)	19% of the core transcriptome significantly differentially expressed between paired <i>ex vivo</i> and generation 1 <i>in vitro</i> samples; distinct clustering by parasite generation observed; upregulation of invasion and replication related genes <i>in vitro</i>	Parasites core gene expression changes substantially upon entering culture

**Table 3**

**Summary of the different levels of analysis performed to assess the effect of short-term parasite culturing on *var* and core gene expression, their rational, method, results, and interpretation.**

continuity and assembled an average of 13% more of the *var* transcripts. This was particularly apparent in the N-terminal region, which has often been poorly characterised by existing approaches. The original approach failed to assemble the N-terminal region in 58% of the samples, compared to just 4% in the new approach with assembly consistently achieved with an accuracy > 90%. This is important because the N-terminal region is known to contribute to the adhesion phenotypes of most PfEMP1 proteins.

The new approach allows for *var* transcript reconstruction across a range of expression levels, which is required when characterising *var* transcripts from multi-clonal infections. Assembly completeness of the lowly expressed *var* genes increased five-fold using the new approach. Biases towards certain parasite stages have been observed in non-severe and severe malaria cases, so it is valuable to assemble the *var* transcripts from different life cycle stages (Tonkin-Hill *et al.*, 2018 [↗](#)). Our new approach is not limited by parasite stage. It was able to assemble the whole *var* transcript, in a single contig, at later stages in the *P. falciparum* 3D7 intra-erythrocytic cycle, something previously unachievable. The new approach allows for a more accurate and complete picture of the *var* transcriptome. It provides new perspectives for relating *var* expression to regulation, co-expression, epigenetics and malaria pathogenesis. It can be applied for example in analysis of patient samples with different clinical outcomes and longitudinal tracking of infections *in vivo*. It represents a crucial improvement for quantifying the *var* transcriptome. In this work, the improved approach for *var* gene assembly and quantification was used to characterise *var* gene expression during transition from *in vivo* to short-term culture.

This study had substantial power through the use of paired samples. However, many *var* gene expression studies do not have longitudinal sampling. Future work should focus on identifying the best approach for analysing the *var* transcripts in cross-sectional samples. Higher level *var* classification systems, such as the PfEMP1 predicted binding phenotype or domain cassettes, could be applied to test for over-representation of different *var* gene features in different groups of interest, because the assumption of overlapping *var* repertoires at these levels of classification would be more realistic. This was briefly explored in our analysis through *var* domain differential expression analysis, which found minimal changes in *var* domain expression through short-term culture, supporting the per patient analysis results. This could be further improved by advancing the classifications of domain subtypes. This has recently been studied using MEME to identify short nucleotide motifs that are representative of domain subtypes (Otto *et al.*, 2019 [↗](#)). Other research could investigate clustering *var* transcripts based on sequence identity and testing for clusters associated with specific malaria disease groups.

Studies have been performed investigating differences between long-term laboratory-adapted clones and clinical isolates, with hundreds of genes found to be differentially expressed (Hoo *et al.*, 2019 [↗](#), Tarr *et al.*, 2018 [↗](#), Mackinnon *et al.*, 2009 [↗](#)). Surprisingly, studies investigating the impact of short-term culture on parasites are extremely limited, despite it being commonly undertaken for making inferences about the *in vivo* transcriptome (Vignali *et al.*, 2011 [↗](#)). Using the new *var* assembly approach, we found that *var* gene expression remains relatively stable during transition to culture. However, the conserved *var2csa* had increased expression from generation 1 to generation 2. It has previously been suggested that long-term cultured parasites converge to expressing *var2csa*, but our findings suggest this begins within two cycles of cultivation (Zhang *et al.*, 2022 [↗](#), Mok *et al.*, 2008 [↗](#)). Switching to *var2csa* has been shown to be favourable and is suggested to be the default *var* gene upon perturbation to *var* specific heterochromatin (Ukaegbu *et al.*, 2015 [↗](#)). These studies also suggested *var2csa* has a unique role in *var* gene switching and our results are consistent with the role of *var2csa* as the dominant “sink node” (Zhang *et al.*, 2022 [↗](#), Ukaegbu *et al.*, 2015 [↗](#), Ukaegbu *et al.*, 2014 [↗](#), Mok *et al.*, 2008 [↗](#)). A previous study suggested *in vitro* cultivation of controlled human malaria infection samples resulted in dramatic changes in *var* gene expression (Lavstsen *et al.*, 2005 [↗](#), Peters *et al.*, 2007 [↗](#)). Almost a quarter of samples in our analysis showed more pronounced and unpredictable changes. In these individuals, the dominant *var* gene being expressed changed within one cycle of cultivation. This

implies short-term culture can result in unpredictable *var* gene expression as observed previously using a semi-quantitative RT-PCR approach (Bachmann *et al.*, 2011 [DOI](#)) and that one would need to confirm *in vivo* expression matches *in vitro* expression. This can be achieved using the assembly approach described here.

We observed no generalised pattern of up- or downregulation of specific *var* groups following transition to culture. This implies there is probably not a selection event occurring during culture but may represent a loss of selection that is present *in vivo*. A global downregulation of certain *var* groups might only occur as a selective process over many cycles in extended culture. Determining changes in *var* group expression levels are difficult using degenerate qPCR primers bias and previous studies have found conflicting results in terms of changes of expression of *var* groups through cultivation. Zhang *et al.*, 2011 [DOI](#) found a rapid transcriptional decline of group A and group B *var* genes, however Peters *et al.*, 2007 [DOI](#) found group A *var* genes to have a high rate of downregulation, when compared to group B *var* genes. These studies differed in the stage distribution of the parasites and were limited in measuring enough variants through their use of primers. Our new approach allowed for the identification of more sequences, with 26.6% of assembled DBLa domains not found via the DBLa-tag approach. This better coverage of the expressed *var* diversity was not possible in these previous studies and may explain discrepancies observed.

Generally, there was a high consensus between all levels of *var* gene analysis and changes observed during short-term *in vitro* cultivation. However, the impact of short-term culture was the most apparent at the *var* transcript level and became less clear at the *var* domain, *var* type and global *var* gene expression level. This highlights the need for accurate characterisation of full length *var* transcripts and analysis of the *var* transcriptome at different levels, both of which can be achieved with the new approach developed here.

We saw striking changes in the core gene transcriptomes between *ex vivo* and generation 1 parasites with 19% of the core genome being differentially expressed. A previous study showed that expression of 18% of core genes were significantly altered after ~50 cycles through culture (Mackinnon *et al.*, 2009 [DOI](#)), but our data suggest that much of this change occurs early in the transition to culture. We observed genes with functions unrelated to ring-stage parasites were among those most significantly expressed in the generation 1 vs *ex vivo* analysis, suggesting the culture conditions may temporarily dysregulate stage-specific expression patterns or result in the parasites undergoing a rapid adaptation response (Andreadaki *et al.*, 2020 [DOI](#), Beeson *et al.*, 2016 [DOI](#)). Several AP2 transcription factors (AP2-SP2, AP2-EXP2, AP2-LT, AP2-O and AP2-HC) were upregulated in generation 1. AP2-HC has been shown to be expressed in asexual parasites (Carrington *et al.*, 2021 [DOI](#)). AP2-O is thought to be specific for the ookinete stage and AP2-SP2 plays a key role in sporozoite stage specific gene expression (Kaneko *et al.*, 2015 [DOI](#), Yuda *et al.*, 2010 [DOI](#)). Our findings are consistent with another study investigating the impact of long-term culture (Mackinnon *et al.*, 2009 [DOI](#)) which also found genes like merozoite surface proteins differentially expressed, however they were downregulated in long-term cultured parasites, whereas we found them upregulated in generation 1. This suggests short-term cultured parasites might be transcriptionally different from long-term cultured parasites, especially in their invasion capabilities, something previously unobserved. Several genes involved in the stress response of parasites were upregulated in generation 1, for example DnaJ proteins, serine proteases and ATP dependent CLP proteases (Oakley *et al.*, 2007 [DOI](#)). The similarity of the core transcriptomes of the *in vitro* samples compared to the heterogeneity seen in the *ex vivo* samples could be explained by a stress response upon entry to culture. Studies investigating whether the dysregulation of stage specific expression and the expression of stress associated genes persist in long-term culture are required to understand whether they are important for growth in culture. Critically, the marked differences presented here suggest the impact of short-term culture can override differences observed in both the *in vivo* core and *var* transcriptomes of different disease manifestations.

In summary, we present an enhanced approach for *var* transcript assembly which allows for *var* gene expression to be studied in connection to *P. falciparum*'s core transcriptome through RNA-sequencing. This will be useful for expanding our understanding of *var* gene regulation and function in *in vivo* samples. As an example of the capabilities of the new approach, the method was used to quantify differences in gene expression upon short-term culture adaptation. This revealed that inferences from clinical isolates of *P. falciparum* put into short-term culture must be made with a degree of caution. Whilst *var* gene expression is often maintained, unpredictable switching does occur, necessitating that the similarity of *in vivo* and *in vitro* expression should be confirmed. The more extreme changes in the core transcriptome could have much bigger implications for understanding other aspects of parasite biology such as growth rates and drug susceptibility and raise a need for additional caution. Further work is needed to examine *var* and core transcriptome changes during longer term culture on a larger sample size. Understanding the ground truth of the *var* expression repertoire of *Plasmodium* field isolates still presents a unique challenge and this work expands the database of *var* sequences globally. The increase in long-read sequencing and the growing size of *var* gene databases containing isolates from across the globe will help overcome this issue in future studies.

## Materials and Methods

### Ethics statement

The study was conducted according to the principles of the Declaration of Helsinki, 6th edition, and the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines. All 32 patients were treated as inpatients or outpatients in Hamburg, Germany (outpatient clinic of the University Medical Center Hamburg-Eppendorf (UKE) at the Bernhard Nocht Institute for Tropical Medicine, UKE, Bundeswehrkrankenhaus) (Wichers *et al.*, 2021 [DOI](#)). Blood samples for this analysis were collected after patients had been informed about the aims and risks of the study and had signed an informed consent form for voluntary blood collection (n=21). In the remaining cases, no intended blood samples were collected but residuals from diagnostic blood samples were used (n=11). The study was approved by the responsible ethics committee (Ethics Committee of the Hamburg Medical Association, reference numbers PV3828 and PV4539).

### Blood sampling, processing and *in vitro* cultivation of *P. falciparum*

EDTA blood samples (1–30 mL) were collected from 32 adult *falciparum* malaria patients for *ex vivo* transcriptome profiling as reported by Wichers *et al.*, 2021 [DOI](#) (Wichers *et al.*, 2021 [DOI](#)), hereafter termed “the original analysis”. Blood was drawn and either immediately processed (#1, #2, #3, #4, #11, #12, #14, #17, #21, #23, #28, #29, #30, #31, #32) or stored overnight at 4°C until processing (#5, #6, #7, #9, #10, #13, #15, #16, #18, #19, #20, #22, #24, #25, #26, #27, #33). If samples were stored overnight, the *ex vivo* and *in vitro* samples were still processed at the same time (so paired samples had similar storage). Erythrocytes were isolated by Ficoll gradient centrifugation, followed by filtration through Plasmodipur filters (EuroProxima) to remove residual granulocytes. At least 400 µl of the purified erythrocytes were quickly lysed in 5 volumes of pre-warmed TRIzol (ThermoFisher Scientific) and stored at –80°C until further processing (“*ex vivo* samples”). When available, the remainder was then transferred to *in vitro* culture either without the addition of allogeneic red cells or with the addition of O+ human red cells (blood bank, UKE) for dilution according to a protocol adopted from Trager and Jensen (Table S5). Cultures were maintained at 37°C in an atmosphere of 1% O<sub>2</sub>, 5% CO<sub>2</sub>, and 94% N<sub>2</sub> using RPMI complete medium containing 10% heat-inactivated human serum (A+, Interstate Blood Bank, Inc., Memphis, USA). Cultures were sampled for RNA purification at the ring stage by microscopic observation of the individual growth of parasite isolates, and harvesting was performed at the appropriate time without prior synchronization treatment (“*in vitro* samples”). 13 of these *ex vivo* samples underwent one cycle of *in vitro* cultivation, ten of these generation 1 samples underwent a second cycle of *in vitro* cultivation. One of these generation 2 samples underwent a third cycle of *in vitro* cultivation.

(Table 1 [↗](#)). In addition, an aliquot of *ex vivo* erythrocytes (approximately 50–100  $\mu$ l) and aliquots of *in vitro* cell cultures collected as indicated in Supplementary file 4 were processed for gDNA purification and MSP1 genotyping as described elsewhere (Wichers *et al.*, 2021 [↗](#), Robert *et al.*, 1996 [↗](#)).

## RNA purification, RNA-sequencing library preparation, and sequencing

RNA purification was performed as described in Wichers *et al.*, 2021 [↗](#), using TRIzol in combination with the RNeasy MinElute Kit (Qiagen) and DNase digestion (DNase I, Qiagen). Human globin mRNA was depleted from all samples except from samples #1 and #2 using the GLOBINclear kit (ThermoFisher Scientific). The median RIN value over all *ex vivo* samples was 6.75 (IQR: 5.93–7.40), although this measurement has only limited significance for samples containing RNA of two species. Accordingly, the RIN value increased upon cultivation for all *in vitro* samples (Supplementary file 5). Customized library construction in accordance to Tonkin-Hill *et al.*, 2018, including amplification with KAPA polymerase and HiSeq 2500 125 bp paired-end sequencing was performed by BGI Genomics Co. (Hong Kong).

## Methods for assembling *var* genes

Previously Oases, Velvet, SoapDeNovo-Trans or MaSuRCA have been used for *var* transcript assembly (Wichers *et al.*, 2021 [↗](#), Andrade *et al.*, 2020 [↗](#), Otto *et al.*, 2019 [↗](#), Tonkin-Hill *et al.*, 2018 [↗](#)). Previous methods either did not incorporate read error correction or focussed on gene assembly, as opposed to transcript assembly (Schulz *et al.*, 2012 [↗](#), Zerbino & Birney, 2008 [↗](#), Xie *et al.*, 2014 [↗](#), Zimin *et al.*, 2013 [↗](#)). Read error correction is important for *var* transcript assembly due to the highly repetitive nature of the *P. falciparum* genome. Recent methods have also focused on whole transcript assembly, as opposed to initial separate domain assembly followed by transcript assembly (Wichers *et al.*, 2021 [↗](#), Andrade *et al.*, 2020 [↗](#), Otto *et al.*, 2019 [↗](#), Tonkin-Hill *et al.*, 2018 [↗](#)). The original analysis used SoapDeNovo-Trans to assemble the *var* transcripts, however it is currently not possible to run all steps in the original approach, due to certain tools being improved and updated. Therefore, SoapDeNovo-Trans (k=71) was used and termed the original approach.

Here, two novel methods for whole *var* transcript and *var* domain assembly were developed and their performance was evaluated in comparison to the original approach (Figure 2b [↗](#)). In both methods the reads were first mapped to the human g38 genome and any mapped reads were removed. Next, the unmapped reads were mapped to a modified *P. falciparum* 3D7 genome with *var* genes removed, to identify multi-mapping reads commonly present in *Plasmodium* RNA-sequencing datasets. Any mapped reads were removed. In parallel, the unmapped RNA reads from the human mapping stage were mapped against a reference of field isolate *var* exon 1 sequences and the mapped reads identified (Otto *et al.*, 2019 [↗](#)). These reads were combined with the unmapped reads from the 3D7 genome mapping stage and duplicate reads removed. All mapping was performed using sub-read align as in the original analysis (Wichers *et al.*, 2021 [↗](#)). The reads identified at the end of this process are referred to as “non-core reads”.

## Whole *var* transcript and *var* domain assembly methods

For whole *var* transcript assembly the non-core reads, for each sample separately, were assembled using rnaSPAdes (k-mer =71, read\_error\_correction on) (Bushmanova *et al.*, 2019 [↗](#)). Contigs were joined into larger scaffolds using SSPACE (parameters `-n 31 -x 0 -k 10`) (Boetzer *et al.*, 2011 [↗](#)). Transcripts < 500nt were excluded, as in the original approach. The included transcripts were annotated using hidden Markov models (HMM) (Finn *et al.*, 2011 [↗](#)) built on the Rask *et al.*, 2010 dataset and used in Tonkin-Hill *et al.*, 2018 [↗](#). When annotating the whole transcript, the most significant alignment was taken as the best annotation for each region of the assembled transcript (e-value cut off 1e-5). Multiple annotations were allowed on the transcript if they were not



overlapping, determined using cath-resolve-hits (Lewis *et al.*, 2019). Scripts are available in the GitHub repository (<https://github.com/ClareAndradiBrown/varAssembly>). In the *var* domain assembly approach, separate domains were assembled first and then joined up to form transcripts. First, the non-core reads were mapped (nucleotide basic local alignment tool (blastn) short read option) to the domain sequences as defined in Rask *et al.*, 2010. This was found to produce similar results when compared to using tblastx. An e-value threshold of 1e-30 was used for the more conserved DBLα domains and an e-value of 1e-10 for the other domains. Next, the reads mapping to the different domains were assembled separately. rnaSPAdes (read\_error\_correction on, k-mer = 15), Oases (kmer = 15) and SoapDeNovo2 (kmer = 15) were all used to assemble the reads separately (Bushmanova *et al.*, 2019; Xie *et al.*, 2014; Schulz *et al.*, 2012). The output of the different assemblers was combined into a per sample reference of domain sequences. Redundancy was removed in the reference using cd-hit (-n 8-c 0.99) (at sequence identity = 99%) (Fu *et al.*, 2012). Cap3 was used to merge and extend the domain assemblies (Huang & Madan, 1999). SSPACE was used to join the domains together (parameters -n 31 -x 0 -k 10) (Boetzer *et al.*, 2011). Transcript annotation was performed as in the whole transcript approach, with transcripts < 500 nt removed. Significantly annotated (1e-5) transcripts were identified and selected. The most significant annotation was selected as the best annotation for each region, with multiple annotations allowed on a single transcript if the regions were not overlapping. For both methods, a *var* transcript was selected if it contained at least one significantly annotated domain (in exon 1). *Var* transcripts that encoded only the more conserved exon 2 (acidic terminal segment (ATS) domain) were discarded.

## Validation on RNA-sequencing dataset from *P. falciparum* reference strain 3D7

Both new approaches and the original approach (SoapDeNovo-Trans, k = 71) (Wichers *et al.*, 2021; Tonkin-Hill *et al.*, 2018) were run on a public RNA-sequencing dataset of the intra-erythrocytic life cycle stages of cultured *P. falciparum* 3D7 strain, sampled at 8-hr intervals up until 40 hrs post infection and then at 4 hr intervals up until 48 hrs post infection (ENA: PRJEB31535) (Wichers *et al.*, 2019). This provided a validation of all three approaches due to the true sequence of the *var* genes being known in *P. falciparum* 3D7 strain. Therefore, we compared the assembled sequences from all three approaches to the true sequence. The first best hit (significance threshold = 1e-10) was chosen for each contig. The alignment score was used to evaluate the performance of each method. The alignment score represents  $\sqrt{\text{accuracy} \times \text{recovery}}$ . The accuracy is the proportion of bases that are correct in the assembled transcript and the recovery reflects what proportion of the true transcript was assembled. Misassemblies were counted as transcripts that had a percentage identity < 99% to their best hit (i.e. the *var* transcript is not 100% contained against the reference).

## Comparison of approaches for *var* assembly on *ex vivo* samples

The *var* transcripts assembled from the 32 *ex vivo* samples using the original approach were compared to those produced from the whole transcript and domain assembly approaches. The whole transcript approach was chosen for subsequent analysis and all assembled *var* transcripts from this approach were combined into a reference, as in the original method (Wichers *et al.*, 2021).

Removal of *var* transcripts with sequence id  $\geq$  99% prior to mapping was not performed in the original analysis. To overcome this, *var* transcripts were removed if they had a sequence id  $\geq$  99% against the full complement in the whole transcript approach, using cd-hit-est (Fu *et al.*, 2012). Removing redundancy in the reference of assembled *var* transcripts across all samples led to the removal of 1,316 assembled contigs generated from the whole transcript approach.



This reference then represented all assembled *var* transcripts across all samples in the given analysis. The same method that was used in the original analysis was applied for quantifying the expression of the assembled *var* transcripts. The non-core reads were mapped against this reference and quantification was performed using Salmon (Patro *et al.*, 2017 [↗](#)). DESeq2 was used to perform differential expression analysis between severe versus non-severe groups and naïve versus pre-exposed groups in the original analysis (Love *et al.*, 2014 [↗](#)). Here, the same approach, as used in the original analysis, was applied to see if concordant expression estimates were obtained. As genomic sequencing was not available, this provided a confirmation of the whole transcript approach after the domain annotation step. The assembled *var* transcripts produced by the whole transcript assembly approach had their expression quantified at the transcript and domain level, as in the original method, and the results were compared to those obtained by the original method. To quantify domain expression, featureCounts was used, as in the original method with the counts for each domain aggregated (Liao *et al.*, 2014 [↗](#)). Correlation analysis between the domain's counts from the whole transcript approach and the original method was performed for each *ex vivo* sample. Differential expression analysis was also performed using DESeq2, as in the original analysis and the results compared (Love *et al.*, 2014 [↗](#), Wichers *et al.*, 2021 [↗](#)).

## Estimation of parasite lifecycle stage distribution in *ex vivo* and short-term *in vitro* samples

To determine the parasite life cycle stage proportions for each sample the mixture model approach of the original analysis (Tonkin-Hill *et al.*, 2018 [↗](#), Wichers *et al.*, 2021 [↗](#)) and the SCDC approach were used (Dong *et al.*, 2021 [↗](#), Howick *et al.*, 2019 [↗](#)). Recently, it has been determined that species-agnostic reference datasets can be used for efficient and accurate gene expression deconvolution of bulk RNA-sequencing data from any *Plasmodium* species and for correct gene expression analyses for biases caused by differences in stage composition among samples (Tebben *et al.*, 2022 [↗](#)). Therefore, the *Plasmodium berghei* single cell atlas was used as reference with restriction to 1:1 orthologs between *P. berghei* and *P. falciparum*. This reference was chosen as it contained reference transcriptomes for the gametocyte stage. To ensure consistency with the original analysis, proportions from the mixture model approach were used for all subsequent analyses (Wichers *et al.*, 2021 [↗](#)). For comparison, the proportion of different stages of the parasite life cycle in the *ex vivo* and *in vitro* samples was determined by two independent readers in Giemsa-stained thin blood smears. The same classification as the mixture model approach was used (8, 19, 30, and 42 hours post infection corresponding to ring, early trophozoite, late trophozoite and schizont stages respectively). Significant differences in ring stage proportions were tested using pairwise Wilcoxon tests. For the other stages, a modified Wilcoxon rank test for zero-inflated data was used (Wang *et al.*, 2021 [↗](#)). *Var* gene expression is highly stage dependent, so any quantitative comparison between samples needs adjustment for developmental stage. The life cycle stage proportions determined from the mixture model approach were used for adjustment.

## Characterising *var* transcripts

The whole transcript approach was applied to the paired *ex vivo* and *in vitro* samples. Significant differences in the number of assembled *var* transcripts and the length of the transcripts across the generations was tested using the paired Wilcoxon test. Redundancy was removed from the assembled *var* transcripts and transcripts and domains were quantified using the approach described above. Three additional filtering steps were applied separately to this reference of assembled *var* transcripts to ensure the *var* transcripts that went on to have their expression quantified represented true *var* transcripts. The first method restricted *var* transcripts to those greater than 1500nt containing at least 3 significantly annotated *var* domains, one of which had to be a DBLα domain. The second restricted *var* transcripts to those greater than 1500nt and containing a DBLα domain. The third approach restricted *var* transcripts to those greater than 1500nt with at least 3 significant *var* domain annotations.

## Per patient *var* transcript expression

A limitation of *var* transcript differential expression analysis is that it assumes all *var* sequences have the possibility of being expressed in all samples. However, since each parasite isolate has a different set of *var* gene sequences, this assumption is not completely valid. To account for this, *var* transcript expression analysis was performed on a per patient basis. For each patient, the paired *ex vivo* and *in vitro* samples were analysed. The assembled *var* transcripts (at least 1500nt and containing 3 significantly annotated *var* domains) across all the generations for a patient were combined into a reference, redundancy was removed as described above, and expression was quantified using Salmon (Patro *et al.*, 2017). *Var* transcript expression was ranked, and the rankings compared across the generations.

## *Var* expression homogeneity (VEH)

VEH is defined as the extent to which a small number of *var* gene sequences dominate an isolate's expression profile (Warimwe *et al.*, 2013). Previously, this has been evaluated by calculating a commonly used diversity index, the Simpson's index of diversity. Different diversity indexes put different weights on evenness and richness. To overcome the issue of choosing one metric, diversity curves were calculated (Wagner *et al.*, 2018). Equation 1 is the computational formula for diversity curves.  $D$  is calculated for  $q$  in the range 0 to 3 with a step increase of 0.1 and  $p$  in this analysis represented the proportion of *var* gene expression dedicated to *var* transcript  $k$ .  $q$  determined how much weight is given to rare vs abundant *var* transcripts. The smaller the  $q$  value, the less weight was given to the more abundant *var* transcript. VEH was investigated on a per patient basis.

$$\text{Equation 1} \quad D_{(q)} = \left( \sum_{k=1}^K p_k^q \right)^{\frac{1}{1-q}}$$

## Conserved *var* gene variants

To check for the differential expression of conserved *var* gene variants *var1-3D7*, *var1-IT* and *var2csa*, all assembled transcripts significantly annotated as such were identified. For each conserved gene, Salmon normalised read counts (adjusted for life cycle stage) were summed and expression compared across the generations using a pairwise Wilcoxon rank test.

## Differential expression of *var* domains from *ex vivo* to *in vitro* samples

Domain expression was quantified using featureCounts, as described above (Liao *et al.*, 2014). DESeq2 was used to test for differential domain expression, with five expected read counts in at least three patient isolates required, with life cycle stage and patient identity used as covariates. For the *ex vivo* versus *in vitro* comparisons, only *ex vivo* samples that had paired samples in generation 1 underwent differential expression analysis, given the extreme nature of the polymorphism seen in the *var* genes.

## *Var* group expression analysis

The type of the *var* gene is determined by multiple parameters: upstream sequence (ups), chromosomal location, direction of transcription and domain composition. All regular *var* genes encode a DBLa domain in the N-terminus of the PfEMP1 protein (Figure 1c). The type of this domain correlates with previously defined *var* gene groups, with group A encoding DBLa1, groups B and C encoding DBLa0 and group B encoding a DBLa2 (chimera between DBLa0 and DBLa1).

(Figure 1c). The DBL $\alpha$  domain sequence for each transcript was determined and for each patient a reference of all assembled DBL $\alpha$  domains combined. The relevant sample's non-core reads were mapped to this using Salmon and DBL $\alpha$  expression quantified (Patro *et al.*, 2017). DESeq2 normalisation was performed, with patient identity and life cycle stage proportions included as covariates and differences in the amounts of *var* transcripts of group A compared with groups B and C assessed (Love *et al.*, 2014). A similar approach was repeated for NTS domains. NTS $\alpha$  domains are found encoded in group A *var* genes and NTS $\beta$  domains are found encoded in group B and C *var* genes (Figure 1c).

## Quantification of total *var* gene expression

The RNA-sequencing reads were blastn (with the short-blastn option on and significance = 1e-10) against the LARSFADIG nucleotide sequences (142 unique LARSFADIG sequences) to identify reads containing the LARSFADIG motifs. This approach has been described previously (Andrade *et al.*, 2020). Once the reads containing the LARSFADIG motifs had been identified, they were used to assemble the LARSFADIG motif. Trinity (Henschel, 2012) and rnaSPAdes (Bushmanova *et al.*, 2019) were used separately to assemble the LARSFADIG motif, and the results compared. The sequencing reads were mapped back against the assemblies using bwa mem (Li, 2013), parameter -k 31 -a (as in Andrade *et al.*, 2020). Coverage over the LARSFADIG motif was assessed by determining the coverage over the middle of the motif (S) using Samtools depth (Danecek *et al.*, 2021). These values were divided by the number of reads mapped to the *var* exon 1 database and the 3D7 genome (which had *var* genes removed) to represent the proportion of total gene expression dedicated to *var* gene expression (similar to an RPKM). The results of both approaches were compared. This method has been validated on 3D7, IT and HB3 *Plasmodium* strains. *Var2csa* does not contain the LARSFADIG motif, hence this quantitative analysis of global *var* gene expression excluded *var2csa* (which was analysed separately). Significant differences in total *var* gene expression were tested by constructing a linear model with the proportion of gene expression dedicated to *var* gene expression as the response variable, the generation and life cycle stage as an independent variables and the patient identity included as a random effect.

## *Var* expression profiling by DBL $\alpha$ -tag sequencing

DBL $\alpha$ -tag sequence analysis was performed as in the original analysis (Wichers *et al.*, 2021), with Varia used to predict domain composition (Mackenzie *et al.*, 2022). The proportion of transcripts encoding NTS $\alpha$ , NTS $\beta$ , DBL $\alpha$ 1, DBL $\alpha$ 2 and DBL $\alpha$ 0 domains were determined for each sample. These expression levels were used as an alternative approach to see whether there were changes in the *var* group expression levels through culture.

The consistency of domain annotations was also investigated between the DBL $\alpha$ -tag approach and the assembled transcripts. This was investigated on a per patient basis, with all the predicted annotations from the DBL $\alpha$ -tag approach for a given patient combined. These were compared to the annotations from all assembled transcripts for a given patient. DBL $\alpha$  annotations and DBL $\alpha$ -CIDR annotations were compared. This provided another validation of the whole transcript approach after the domain annotation step and was not dependent on performing differential expression analysis.

For comparison of both approaches (DBL $\alpha$ -tag sequencing and our new whole transcript approach), the same analysis was performed as in the original analysis (Wichers *et al.*, 2021). All conserved variants (*var1*, *var2csa* and *var3*) were removed as they were not properly amplified by the DBL $\alpha$ -tag approach. To identify how many assembled transcripts, specifically the DBL $\alpha$  region, were found in the DBL $\alpha$ -tag approach, we applied BLAST. As in the original analysis, a BLAST database was created from the DBL $\alpha$ -tag cluster results and screened for the occurrence of those assembled DBL $\alpha$  regions with more than 97% seq id using the “megablast” option. This was restricted to the assembled DBL $\alpha$  regions that were expressed in the top 75<sup>th</sup> percentile to allow for a fair comparison, as only DBL $\alpha$ -tag clusters with more than 10 reads were considered.

Similarly, to identify how many DBL $\alpha$ -tag sequences were found in the assembled transcripts, a BLAST database was created from the assembled transcripts and screened for the occurrence of the DBL $\alpha$ -tag sequences with more than 97% seq id using the “megablast” option. This was performed for each sample.

## Core gene differential expression analysis

Subread align was used, as in the original analysis, to align the reads to the human genome and *P. falciparum* 3D7 genome, with *var*, *rif*, *stevor*, *surf* and *rRNA* genes removed (Liao *et al.*, 2013 [↗](#)). HTSeq count was used to quantify gene counts (Anders *et al.*, 2015 [↗](#)). DESeq2 was used to test for differentially expressed genes with five read counts in at least three samples being required (Love *et al.*, 2014 [↗](#)). Parasite life cycle stages and patient identity were included as covariates. GO and KEGG analysis was performed using ShinyGo and significant terms were defined by having a Bonferroni corrected p-value < 0.05 (Ge *et al.*, 2020 [↗](#)).

## Funding / Acknowledgements

CAB received support from the Wellcome Trust (4-Year PhD programme, grant number 220123/Z/20/Z). Infrastructure support for this research was provided by the NIHR Imperial Biomedical Research Centre and Imperial College Research Computing Service, DOI: 10.14469/hpc/2232.

JSWM, YDH and AB were funded by the German Research Foundation (DFG) grants BA 5213/3-1 (project #323759012) and BA 5213/6-1 (project #433302244).

TO is supported by the Wellcome Trust grant 104111/Z/14/ZR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

JB acknowledges support from Wellcome (100993/Z/13/Z)

## Author contribution

Conceptualization: CAB, TDO, AB, AJC

Methodology: CAB, MFD, TL, TDO

Software: CAB

Validation: CAB, AB

Formal analysis: CAB

Investigation: JSW, HvT, YDH, JAMS, HSH, EFH, AB

Resources: TL, AJC, AB

Data curation: CAB, AB

Writing – original draft: CAB, TDO, AJC, AB

Writing – review & editing: CAB, JSW, MFD, TL, TWG, JB, TDO, AJC, AB

Visualization: CAB

Supervision: TWG, JB, TDO, AJC, AB

Project Administration: CAB, AJC, AB

Funding acquisition: AJC, AB

All authors read and approved the manuscript.

## Competing interests

No competing interests declared.

## References

1. Almelli T. *et al.* (2014) **Differences in gene transcriptomic pattern of *Plasmodium falciparum* in children with cerebral malaria and asymptomatic carriers** *PLoS One* **9**
2. Anders S., Pyl P.T., Huber W (2015) **HTSeq--a Python framework to work with high-throughput sequencing data** *Bioinformatics* **31**:166–169
3. Andrade C.M. *et al.* (2020) **Increased circulation time of *Plasmodium falciparum* underlies persistent asymptomatic infection in the dry season** *Nat Med* **26**:1929–1940
4. Andreadaki M., Pace T., Grasso F., Siden-Kiamos I., Mochi S., Picci L., Bertuccini L., Ponzi M., Curra C (2020) ***Plasmodium berghei* Gamete Egress Protein is required for fertility of both genders** *Microbiologyopen* **9**
5. Avril M., Tripathi A.K., Brazier A.J., Andisi C., Janes J.H., Soma V.L., Sullivan D.J., Bull P.C., Stins M.F., Smith J.D (2012) **A restricted subset of var genes mediates adherence of *Plasmodium falciparum*-infected erythrocytes to brain endothelial cells** *Proc Natl Acad Sci U S A* **109**:E1782–1790
6. Bachmann A., Predehl S., May J., Harder S., Burchard G.D., Gilberger T.W., Tannich E., Bruchhaus I (2011) **Highly co-ordinated var gene expression and switching in clinical *Plasmodium falciparum* isolates from non-immune malaria patients** *Cell Microbiol* **13**:1397–1409
7. Baruch D.I., Pasloske B.L., Singh H.B., Bi X., Ma X.C., Feldman M., Taraschi T.F., Howard R.J (1995) **Cloning the *P. falciparum* gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes** *Cell* **82**:77–87
8. Beeson J.G., Drew D.R., Boyle M.J., Feng G., Fowkes F.J., Richards J.S (2016) **Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria** *FEMS Microbiol Rev* **40**:343–372
9. Bernabeu M. *et al.* (2016) **Severe adult malaria is associated with specific PfEMP1 adhesion types and high parasite biomass** *Proc Natl Acad Sci U S A* **113**:E3270–3279
10. Boetzer M., Henkel C.V., Jansen H.J., Butler D., Pirovano W (2011) **Scaffolding pre-assembled contigs using SSPACE** *Bioinformatics* **27**:578–579
11. Bozdech Z., Llinas M., Pulliam B.L., Wong E.D., Zhu J., DeRisi J.L (2003) **The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*** *PLoS Biol* **1**
12. Brown A.C., Guler J.L (2020) **From Circulation to Cultivation: *Plasmodium* In Vivo versus In Vitro** *Trends Parasitol* **36**:914–926
13. Bruske E.I., Dimonte S., Enderes C., Tschan S., Flotenmeyer M., Koch I., Berger J., Kremsner P., Frank M (2016) **In Vitro Variant Surface Antigen Expression in *Plasmodium falciparum* Parasites from a Semi-Immune Individual Is Not Correlated with Var Gene Transcription** *PLoS One* **11**



14. Bushmanova E., Antipov D., Lapidus A., Pribelski A.D (2019) **rnaSPAdes: a de novo transcriptome assembler and its application to RNA-Seq data** *Gigascience* **8**
15. Carrington E., Cooijmans R.H.M., Keller D., Toenhake C.G., Bartfai R., Voss T.S (2021) **The ApiAP2 factor PfAP2-HC is an integral component of heterochromatin in the malaria parasite Plasmodium falciparum** *iScience* **24**
16. Claessens A. *et al.* (2012) **A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells** *Proc Natl Acad Sci U S A* **109**:E1772–1781
17. Claessens A., Affara M., Assefa S.A., Kwiatkowski D.P., Conway D.J (2017) **Culture adaptation of malaria parasites selects for convergent loss-of-function mutants** *Sci Rep* **7**
18. Danecek P. *et al.* (2021) **Twelve years of SAMtools and BCFtools** *Gigascience* **10**
19. Dimonte S. *et al.* (2016) **Sporozoite Route of Infection Influences In Vitro var Gene Transcription of Plasmodium falciparum Parasites From Controlled Human Infections** *J Infect Dis* **214**:884–894
20. Dong M., Thennavan A., Urrutia E., Li Y., Perou C.M., Zou F., Jiang Y (2021) **SCDC: bulk gene expression deconvolution by multiple single-cell RNA sequencing references** *Brief Bioinform* **22**:416–427
21. Finn R.D., Clements J., Eddy S.R (2011) **HMMER web server: interactive sequence similarity searching** *Nucleic Acids Res* **39**:W29–37
22. Fu L., Niu B., Zhu Z., Wu S., Li W (2012) **CD-HIT: accelerated for clustering the next-generation sequencing data** *Bioinformatics* **28**:3150–3152
23. Ge S.X., Jung D., Yao R (2020) **ShinyGO: a graphical gene-set enrichment tool for animals and plants** *Bioinformatics* **36**:2628–2629
24. Guillochon E. *et al.* (2022) **Transcriptome Analysis of Plasmodium falciparum Isolates From Benin Reveals Specific Gene Expression Associated With Cerebral Malaria** *J Infect Dis* **225**:2187–2196
25. Henschel R., Lieber M., Wu L., Nista P. M., Haas B. J., LeDuc R. D (2012) **Trinity RNA-Seq assembler performance optimization. In: XSEDE '12: Proceedings of the 1st Conference of the Extreme Science and Engineering Discovery Environment: Bridging from the eXtreme to the campus and beyond** :1–8
26. Hoo R. *et al.* (2019) **Transcriptome profiling reveals functional variation in Plasmodium falciparum parasites from controlled human malaria infection studies** *EBioMedicine* **48**:442–452
27. Howick V.M. *et al.* (2019) **The Malaria Cell Atlas: Single parasite transcriptomes across the complete Plasmodium life cycle** *Science* **365**
28. Huang X., Madan A (1999) **CAP3: A DNA sequence assembly program** *Genome Res* **9**:868–877
29. Jensen A.T. *et al.* (2004) **Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes** *J Exp Med* **199**:1179–1190

30. Jespersen J.S., Wang C.W., Mkumbaye S.I., Minja D.T., Petersen B., Turner L., Petersen J.E., Lusingu J.P., Theander T.G., Lavstsen T (2016) **Plasmodium falciparum var genes expressed in children with severe malaria encode CIDRalpha1 domains** *EMBO Mol Med* **8**:839–850
31. Joste V. *et al.* (2020) **PfEMP1 A-Type ICAM-1-Binding Domains Are Not Associated with Cerebral Malaria in Beninese Children** *mBio* **11**
32. Kaneko I., Iwanaga S., Kato T., Kobayashi I., Yuda M (2015) **Genome-Wide Identification of the Target Genes of AP2-O, a Plasmodium AP2-Family Transcription Factor** *PLoS Pathog* **11**
33. Kessler A. *et al.* (2017) **Linking EPCR-Binding PfEMP1 to Brain Swelling in Pediatric Cerebral Malaria** *Cell Host Microbe* **22**:601–614
34. Kirchgatter K., Portillo Hdel A (2002) **Association of severe noncerebral Plasmodium falciparum malaria in Brazil with expressed PfEMP1 DBL1 alpha sequences lacking cysteine residues** *Mol Med* **8**:16–23
35. Kraemer S.M., Smith J.D (2003) **Evidence for the importance of genetic structuring to the structural and functional specialization of the Plasmodium falciparum var gene family** *Mol Microbiol* **50**:1527–1538
36. Kyes S.A., Kraemer S.M., Smith J.D (2007) **Antigenic variation in Plasmodium falciparum: gene organization and regulation of the var multigene family** *Eukaryot Cell* **6**:1511–1520
37. Lavstsen T., Magistrado P., Hermesen C.C., Salanti A., Jensen A.T., Sauerwein R., Hviid L., Theander T.G., Staalsoe T (2005) **Expression of Plasmodium falciparum erythrocyte membrane protein 1 in experimentally infected humans** *Malar J* **4**
38. Lavstsen T., Salanti A., Jensen A.T., Arnot D.E., Theander T.G (2003) **Sub-grouping of Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding regions** *Malar J* **2**
39. Lavstsen T. *et al.* (2012) **Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8 and 13 are associated with severe malaria in children** *Proc Natl Acad Sci U S A* **109**:E1791–1800
40. Lee H.J., Georgiadou A., Walther M., Nwakanma D., Stewart L.B., Levin M., Otto T.D., Conway D.J., Coin L.J., Cunningham A.J (2018) **Integrated pathogen load and dual transcriptome analysis of systemic host-pathogen interactions in severe malaria** *Sci Transl Med* **10**
41. Leech J.H., Barnwell J.W., Miller L.H., Howard R.J (1984) **Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes** *J Exp Med* **159**:1567–1575
42. Lewis T.E., Sillitoe I., Lees J.G (2019) **cath-resolve-hits: a new tool that resolves domain matches suspiciously quickly** *Bioinformatics* **35**:1766–1767
43. Li H (2013) **Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM** *arXiv* **1303**
44. Liao Y., Smyth G.K., Shi W (2013) **The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote** *Nucleic Acids Res* **41**

45. Liao Y., Smyth G.K., Shi W (2014) **featureCounts: an efficient general purpose program for assigning sequence reads to genomic features** *Bioinformatics* **30**:923–930
46. Lischer H.E.L., Shimizu K.K (2017) **Reference-guided de novo assembly approach improves genome reconstruction for related species** *BMC Bioinformatics* **18**
47. Love M.I., Huber W., Anders S (2014) **Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2** *Genome Biol* **15**
48. Mackenzie G., Jensen R.W., Lavstsen T., Otto T.D (2022) **Varia: a tool for prediction, analysis and visualisation of variable genes** *BMC Bioinformatics* **23**
49. Mackinnon M.J., Li J., Mok S., Kortok M.M., Marsh K., Preiser P.R., Bozdech Z (2009) **Comparative transcriptional and genomic analysis of Plasmodium falciparum field isolates** *PLoS Pathog* **5**
50. MalariaGen Ahouidi A. *et al.* (2021) **An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples** *Wellcome Open Res* **6**
51. Mkumbaye S.I. *et al.* (2017) **The Severity of Plasmodium falciparum Infection Is Associated with Transcript Levels of var Genes Encoding Endothelial Protein C Receptor-Binding P. falciparum Erythrocyte Membrane Protein 1** *Infect Immun* **85**
52. Mok B.W., Ribacke U., Rasti N., Kironde F., Chen Q., Nilsson P., Wahlgren M (2008) **Default Pathway of var2csa switching and translational repression in Plasmodium falciparum** *PLoS One* **3**
53. Oakley M.S., Kumar S., Anantharaman V., Zheng H., Mahajan B., Haynes J.D., Moch J.K., Fairhurst R., McCutchan T.F., Aravind L (2007) **Molecular factors and biochemical pathways induced by febrile temperature in intraerythrocytic Plasmodium falciparum parasites** *Infect Immun* **75**:2012–2025
54. Otto T.D., Assefa S.A., Bohme U., Sanders M.J., Kwiatkowski D, Pf3k, c., Berriman M., Newbold C. (2019) **Evolutionary analysis of the most polymorphic gene family in falciparum malaria** *Wellcome Open Res* **4**
55. Patro R., Duggal G., Love M.I., Irizarry R.A., Kingsford C (2017) **Salmon provides fast and bias-aware quantification of transcript expression** *Nat Methods* **14**:417–419
56. Peters J.M., Fowler E.V., Krause D.R., Cheng Q., Gattton M.L (2007) **Differential changes in Plasmodium falciparum var transcription during adaptation to culture** *J Infect Dis* **195**:748–755
57. Pickford A.K., Michel-Todo L., Dupuy F., Mayor A., Alonso P.L., Lavazec C., Cortes A (2021) **Expression Patterns of Plasmodium falciparum Clonally Variant Genes at the Onset of a Blood Infection in Malaria-Naive Humans** *mBio* **12**
58. Quintana M.D.P., Ecklu-Mensah G., Tcherniuk S.O., Ditlev S.B., Oleinikov A.V., Hviid L., Lopez-Perez M (2019) **Comprehensive analysis of Fc-mediated IgM binding to the Plasmodium falciparum erythrocyte membrane protein 1 family in three parasite clones** *Sci Rep* **9**
59. Rask T.S., Hansen D.A., Theander T.G., Gorm Pedersen A., Lavstsen T (2010) **Plasmodium falciparum erythrocyte membrane protein 1 diversity in seven genomes--divide and conquer** *PLoS Comput Biol* **6**

60. Robert F., Ntoumi F., Angel G., Candito D., Rogier C., Fandeur T., Sarthou J.L., Mercereau-Puijalon O (1996) **Extensive genetic diversity of *Plasmodium falciparum* isolates collected from patients with severe malaria in Dakar, Senegal** *Trans R Soc Trop Med Hyg* **90**:704–711
61. Rorick M.M., Rask T.S., Baskerville E.B., Day K.P., Pascual M (2013) **Homology blocks of *Plasmodium falciparum* var genes and clinically distinct forms of severe malaria in a local population** *BMC Microbiol* **13**
62. Sahu P.K. *et al.* (2021) **Determinants of brain swelling in pediatric and adult cerebral malaria** *JCI Insight* **6**
63. Salanti A. *et al.* (2004) **Evidence for the involvement of VAR2CSA in pregnancy-associated malaria** *J Exp Med* **200**:1197–1203
64. Scherf A., Hernandez-Rivas R., Buffet P., Bottius E., Benatar C., Pouvelle B., Gysin J., Lanzer M (1998) **Antigenic variation in malaria: in situ switching, relaxed and mutually exclusive transcription of var genes during intra-erythrocytic development in *Plasmodium falciparum*** *EMBO J* **17**:5418–5426
65. Schulz M.H., Zerbino D.R., Vingron M., Birney E (2012) **Oases: robust de novo RNA-seq assembly across the dynamic range of expression levels** *Bioinformatics* **28**:1086–1092
66. Shabani E., Hanisch B., Opoka R.O., Lavstsen T., John C.C (2017) ***Plasmodium falciparum* EPCR-binding PfEMP1 expression increases with malaria disease severity and is elevated in retinopathy negative cerebral malaria** *BMC Med* **15**
67. Smith J.D., Chitnis C.E., Craig A.G., Roberts D.J., Hudson-Taylor D.E., Peterson D.S., Pinches R., Newbold C.I., Miller L.H (1995) **Switches in expression of *Plasmodium falciparum* var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes** *Cell* **82**:101–110
68. Stevenson L., Laursen E., Cowan G.J., Bando B., Barfod L., Cavanagh D.R., Andersen G.R., Hviid L (2015) **alpha2-Macroglobulin Can Crosslink Multiple *Plasmodium falciparum* Erythrocyte Membrane Protein 1 (PfEMP1) Molecules and May Facilitate Adhesion of Parasitized Erythrocytes** *PLoS Pathog* **11**
69. Storm J. *et al.* (2019) **Cerebral malaria is associated with differential cytoadherence to brain endothelial cells** *EMBO Mol Med* **11**
70. Su X.Z., Heatwole V.M., Wertheimer S.P., Guinet F., Herrfeldt J.A., Peterson D.S., Ravetch J.A., Wellems T.E (1995) **The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes** *Cell* **82**:89–100
71. Tarr S.J. *et al.* (2018) **Schizont transcriptome variation among clinical isolates and laboratory-adapted clones of the malaria parasite *Plasmodium falciparum*** *BMC Genomics* **19**
72. Taylor H.M., Grainger M., Holder A.A (2002) **Variation in the expression of a *Plasmodium falciparum* protein family implicated in erythrocyte invasion** *Infect Immun* **70**:5779–5789
73. Tebben K., Dia A., Serre D. (2022) **Determination of the Stage Composition of *Plasmodium* Infections from Bulk Gene Expression Data** *mSystems* **7**

74. Tonkin-Hill G.Q. *et al.* (2018) **The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes** *PLoS Biol* **16**
75. Tuikue Ndam N. *et al.* (2017) **Parasites Causing Cerebral Falciparum Malaria Bind Multiple Endothelial Receptors and Express EPCR and ICAM-1-Binding PfEMP1** *J Infect Dis* **215**:1918–1925
76. Turner L. *et al.* (2013) **Severe malaria is associated with parasite binding to endothelial protein C receptor** *Nature* **498**:502–505
77. Ukaegbu U.E., Kishore S.P., Kwiatkowski D.L., Pandarinath C., Dahan-Pasternak N., Dzikowski R., Deitsch K.W (2014) **Recruitment of PfSET2 by RNA polymerase II to variant antigen encoding loci contributes to antigenic variation in P. falciparum** *PLoS Pathog* **10**
78. Ukaegbu U.E., Zhang X., Heinberg A.R., Wele M., Chen Q., Deitsch K.W (2015) **A Unique Virulence Gene Occupies a Principal Position in Immune Evasion by the Malaria Parasite Plasmodium falciparum** *PLoS Genet* **11**
79. Vignali M. *et al.* (2011) **NSR-seq transcriptional profiling enables identification of a gene signature of Plasmodium falciparum parasites infecting children** *J Clin Invest* **121**:1119–1129
80. Wagner B.D., Grunwald G.K., Zerbe G.O., Mikulich-Gilbertson S.K., Robertson C.E., Zemanick E.T., Harris J.K (2018) **On the Use of Diversity Measures in Longitudinal Sequencing Studies of Microbial Communities** *Front Microbiol* **9**
81. Wahlgren M., Goel S., Akhouri R.R (2017) **Variant surface antigens of Plasmodium falciparum and their roles in severe malaria** *Nat Rev Microbiol* **15**:479–491
82. Wang W., Chen E.Z., Li H. (2021) **Truncated Rank-Based Tests for Two-Part Models with Excessive Zeros and Applications to Microbiome Data** *arXiv*
83. Warimwe G.M., Recker M., Kiragu E.W., Buckee C.O., Wambua J., Musyoki J.N., Marsh K., Bull P.C (2013) **Plasmodium falciparum var gene expression homogeneity as a marker of the host-parasite relationship under different levels of naturally acquired immunity to malaria** *PLoS One* **8**
84. WHO (2022) **World malaria report**
85. Wichers J.S. *et al.* (2019) **Dissecting the Gene Expression, Localization, Membrane Topology, and Function of the Plasmodium falciparum STEVOR Protein Family** *mBio* **10**
86. Wichers J.S. *et al.* (2021) **Common virulence gene expression in adult first-time infected malaria patients and severe cases** *Elife* **10**
87. Xie Y. *et al.* (2014) **SOAPdenovo-Trans: de novo transcriptome assembly with short RNA-Seq reads** *Bioinformatics* **30**:1660–1666
88. Yamagishi J. *et al.* (2014) **Interactive transcriptome analysis of malaria patients and infecting Plasmodium falciparum** *Genome Res* **24**:1433–1444
89. Yang X., Charlebois P., Gnerre S., Coole M.G., Lennon N.J., Levin J.Z., Qu J., Ryan E.M., Zody M.C., Henn M.R (2012) **De novo assembly of highly diverse viral populations** *BMC Genomics* **13**

90. Yuda M., Iwanaga S., Shigenobu S., Kato T., Kaneko I (2010) **Transcription factor AP2-Sp and its target genes in malarial sporozoites** *Mol Microbiol* **75**:854–863
91. Zerbino D.R., Birney E (2008) **Velvet: algorithms for de novo short read assembly using de Bruijn graphs** *Genome Res* **18**:821–829
92. Zhang Q., Zhang Y., Huang Y., Xue X., Yan H., Sun X., Wang J., McCutchan T.F., Pan W (2011) **From in vivo to in vitro: dynamic analysis of Plasmodium falciparum var gene expression patterns of patient isolates during adaptation to culture** *PLoS One* **6**
93. Zhang X., Florini F., Visone J.E., Lionardi I., Gross M.R., Patel V., Deitsch K.W (2022) **A coordinated transcriptional switching network mediates antigenic variation of human malaria parasites** *Elife* **11**
94. Zimin A.V., Marcais G., Puiu D., Roberts M., Salzberg S.L., Yorke J.A (2013) **The MaSuRCA genome assembler** *Bioinformatics* **29**:2669–2677

## Article and author information

### Clare Andradi-Brown

Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, UK, Department of Life Sciences, Imperial College London, South Kensington, London, SW7 2AZ, UK, Centre for Paediatrics and Child Health, Imperial College London, UK

### Jan Stephan Wichers-Misterek

Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany, Biology Department, University of Hamburg, Hamburg, Germany  
ORCID iD: [0000-0002-0599-1742](https://orcid.org/0000-0002-0599-1742)

### Heidrun von Thien

Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany, Biology Department, University of Hamburg, Hamburg, Germany

### Yannick D. Höppner

Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany, Biology Department, University of Hamburg, Hamburg, Germany

### Judith A. M. Scholz

Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany

### Helle Hansson

Center for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark, Department of Infectious Diseases, Copenhagen University Hospital, 2200 Copenhagen, Denmark  
ORCID iD: [0000-0001-6484-1165](https://orcid.org/0000-0001-6484-1165)

### Emma Filtenborg Hocke

Center for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark, Department of Infectious Diseases, Copenhagen University Hospital, 2200 Copenhagen, Denmark



**Tim-Wolf Gilberger**

Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany, Biology Department, University of Hamburg, Hamburg, Germany  
ORCID iD: [0000-0002-7965-8272](https://orcid.org/0000-0002-7965-8272)

**Michael F. Duffy**

Department of Microbiology and Immunology, University of Melbourne, Melbourne/Parkville VIC 3052, Australia

**Thomas Lavstsen**

Center for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, 2200 Copenhagen, Denmark, Department of Infectious Diseases, Copenhagen University Hospital, 2200 Copenhagen, Denmark  
ORCID iD: [0000-0002-3044-4249](https://orcid.org/0000-0002-3044-4249)

**Jake Baum**

Department of Life Sciences, Imperial College London, South Kensington, London, SW7 2AZ, UK, School of Biomedical Sciences, Faculty of Medicine & Health, UNSW, Kensington, Sydney, 2052, Australia

**Thomas D. Otto**

School of Infection & Immunity, MVLS, University of Glasgow, UK  
ORCID iD: [0000-0002-1246-7404](https://orcid.org/0000-0002-1246-7404)

**Aubrey J. Cunningham**

Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, UK, Centre for Paediatrics and Child Health, Imperial College London, UK  
**For correspondence:** [a.cunnington@imperial.ac.uk](mailto:a.cunnington@imperial.ac.uk)  
ORCID iD: [0000-0002-1305-3529](https://orcid.org/0000-0002-1305-3529)

**Anna Bachmann**

Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany, Biology Department, University of Hamburg, Hamburg, Germany, German Center for Infection Research (DZIF), partner site Hamburg-Borstel-Lübeck-Riems, Germany  
**For correspondence:** [bachmann@bni-hamburg.de](mailto:bachmann@bni-hamburg.de)  
ORCID iD: [0000-0001-8397-7308](https://orcid.org/0000-0001-8397-7308)

**Copyright**

© 2023, Andradi-Brown et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

**Editors**

Reviewing Editor

**Urszula Krzych**

Walter Reed Army Institute of Research, Silver Spring, United States of America

Senior Editor

**David James**

University of Sydney, Sydney, Australia

**Reviewer #1 (Public Review):**

The authors took advantage of a large dataset of transcriptomic information obtained from parasites recovered from 35 patients. In addition, parasites from 13 of these patients were reared for 1 generation in vivo, 10 for 2 generations, and 1 for a third generation. This provided the authors with a remarkable resource for monitoring how parasites initially adapt to the environmental change of being grown in culture. They focused initially on var gene expression due to the importance of this gene family for parasite virulence, then subsequently assessed changes in the entire transcriptome. Their goal was to develop a more accurate and informative computational pipeline for assessing var gene expression and secondly, to document the adaptation process at the whole transcriptome level.

Overall, the authors were largely successful in their aims. They provide convincing evidence that their new computational pipeline is better able to assemble var transcripts and assess the structure of the encoded PfEMP1s. They can also assess var gene switching as a tool for examining antigenic variation. They also documented potentially important changes in the overall transcriptome that will be important for researchers who employ ex vivo samples for assessing things like drug sensitivity profiles or metabolic states. These are likely to be important tools and insights for researchers working on field samples.

Interestingly, the conclusions about changes in var gene expression due to the transition to in vitro culture (one of the primary goals of the paper) were somewhat difficult to assess. The authors found that in most instances, var gene expression patterns changed only modestly. However, in a few cases, more substantial changes were observed. Thus, it is difficult to make firm conclusions about how one should interpret var gene expression profiles in parasites recently placed in culture. Changes in the core transcriptome however were more pronounced, justifying the authors recommendation for caution when interpreting the results of such experiments.

- <https://doi.org/10.7554/eLife.87726.2.sa2>

**Reviewer #2 (Public Review):**

In this study, the authors describe a pipeline to sequence expressed var genes from RNA sequencing that improves on a previous one that they had developed. Importantly, they use this approach to determine how var gene expression changes with short-term culture. Their finding of shifts in the expression of particular var genes is compelling and casts some doubt on the comparability of gene expression in short-term culture versus var expression at the time of participant sampling.

Other studies have relied on short-term culture to understand var gene expression in clinical malaria studies. This study indicates the need for caution in over-interpreting findings from these studies.

We appreciate the careful attention of the authors to our comments and the edits that have been made. One additional suggestion that would be helpful to readers is to include in Table S1 the new approach described in the manuscript. This will provide the reader a direct means of comparing what the authors have done to past work.

- <https://doi.org/10.7554/eLife.87726.2.sa1>

**Reviewer #3 (Public Review):**

This research addresses a critical challenge in malaria research, specifically how to effectively access the highly polymorphic var gene family using short-read sequence data. The authors successfully tackled this issue by introducing an optimization of their original de novo assembler, which notably more than doubled the N50 metric and greatly improved the assembly of var genes.

The most intriguing aspect of this study lies in its methodologies, particularly the longitudinal analysis of assembled var transcripts within subjects. This approach allows for the construction of an unbiased var repertoire for each individual, free from the influence of a reference genome or other samples. These sample-specific var gene repertoires are then tracked over time in culture to evaluate the reliability of using cultured samples for inferences about in vivo expression patterns. The findings from this analysis are thought-provoking. While the authors conclude that culturing parasites can lead to unpredictable transcriptional changes, they also observe that the overall ranking of each var gene remains relatively robust over time. This resilience in the var gene ranking within individuals raises intriguing questions about the mechanisms behind var gene switching and adaptation during short-term culture.

In addition to the var gene-specific analysis, the study also delves into a comparison of ex vivo samples with generation 1 and generation 2 cultured parasites across the core genome. This analysis reveals substantial shifts in expression due to culture adaptation, shedding light on broader changes in the parasite transcriptome during short-term culture.

In summary, this research contributes to our understanding of var gene expression and potentially associations with disease. It emphasizes the importance of improved assembly techniques to access var genes and underscores the challenges of using short-term cultured parasites to infer in vivo characteristics. The longitudinal analysis approach offers a fresh perspective on var gene dynamics within individuals and highlights the need for further investigations into var gene switching and adaptation during culture.

- <https://doi.org/10.7554/eLife.87726.2.sa0>

**Author Response**

The following is the authors' response to the original reviews.

***eLife assessment:***

*This important study represents a comprehensive computational analysis of Plasmodium falciparum gene expression, with a focus on var gene expression, in parasites isolated from patients; it assesses changes that occur as the parasites adapt to short-term in vitro culture conditions. The work provides technical advances to update a previously developed computational pipeline. Although the findings of the shifts in the expression of particular var genes have theoretical or practical implications beyond a single subfield, the results are incomplete and the main claims are only partially supported.*

The authors would like to thank the reviewers and editors for their insightful and constructive assessment. We particularly appreciate the statement that our work provides a technical advance of our computational pipeline given that this was one of our main aims. To address the editorial criticisms, we have rephrased and restructured the manuscript to ensure clarity of results and to support our main claims. For the same reason, we removed the var transcript differential expression analysis, as this led to confusion.

## Public Reviews:

### Reviewer #1:

*The authors took advantage of a large dataset of transcriptomic information obtained from parasites recovered from 35 patients. In addition, parasites from 13 of these patients were reared for 1 generation in vivo, 10 for 2 generations, and 1 for a third generation. This provided the authors with a remarkable resource for monitoring how parasites initially adapt to the environmental change of being grown in culture. They focused initially on var gene expression due to the importance of this gene family for parasite virulence, then subsequently assessed changes in the entire transcriptome. Their goal was to develop a more accurate and informative computational pipeline for assessing var gene expression and secondly, to document the adaptation process at the whole transcriptome level.*

*Overall, the authors were largely successful in their aims. They provide convincing evidence that their new computational pipeline is better able to assemble var transcripts and assess the structure of the encoded PfEMP1s. They can also assess var gene switching as a tool for examining antigenic variation. They also documented potentially important changes in the overall transcriptome that will be important for researchers who employ ex vivo samples for assessing things like drug sensitivity profiles or metabolic states. These are likely to be important tools and insights for researchers working on field samples.*

*One concern is that the abstract highlights "Unpredictable var gene switching..." and states that "Our results cast doubt on the validity of the common practice of using short-term cultured parasites...". This seems somewhat overly pessimistic with regard to var gene expression profiling and does not reflect the data described in the paper. In contrast, the main text of the paper repeatedly refers to "modest changes in var gene expression repertoire upon culture" or "relatively small changes in var expression from ex vivo to culture", and many additional similar assessments. On balance, it seems that transition to culture conditions causes relatively minor changes in var gene expression, at least in the initial generations. The authors do highlight that a few individuals in their analysis showed more pronounced and unpredictable changes, which certainly warrants caution for future studies but should not obscure the interesting observation that var gene expression remained relatively stable during transition to culture.*

Thank you for this comment. We were happy to modify the wording in the abstract to have consistency with the results presented by highlighting that modest but unpredictable var gene switching was observed while substantial changes were found in the core transcriptome. Moreover, any differences observed in core transcriptome between ex vivo samples from naïve and pre-exposed patients are diminished after one cycle of cultivation making inferences about parasite biology in vivo impossible.

Therefore, – to our opinion – the statement in the last sentence is well supported by the data presented.

Line 43–47: “Modest but unpredictable var gene switching and convergence towards var2csa were observed in culture, along with differential expression of 19% of the core transcriptome between paired ex vivo and generation 1 samples. Our results cast doubt on the validity of the common practice of using short-term cultured parasites to make inferences about in vivo phenotype and behaviour.” Nevertheless, we would like to note that this study was in a unique position to assess changes at the individual patient level as we had successive parasite generations. This comparison is not done in most cross-sectional studies and therefore these small, unpredictable changes in the var transcriptome are missed.

## Reviewer #2:

*In this study, the authors describe a pipeline to sequence expressed var genes from RNA sequencing that improves on a previous one that they had developed. Importantly, they use this approach to determine how var gene expression changes with short-term culture. Their finding of shifts in the expression of particular var genes is compelling and casts some doubt on the comparability of gene expression in short-term culture versus var expression at the time of participant sampling. The authors appear to overstate the novelty of their pipeline, which should be better situated within the context of existing pipelines described in the literature.*

*Other studies have relied on short-term culture to understand var gene expression in clinical malaria studies. This study indicates the need for caution in over-interpreting findings from these studies.*

*The novel method of var gene assembly described by the authors needs to be appropriately situated within the context of previous studies. They neglect to mention several recent studies that present transcript-level novel assembly of var genes from clinical samples. It is important for them to situate their work within this context and compare and contrast it accordingly. A table comparing all existing methods in terms of pros and cons would be helpful to evaluate their method.*

We are grateful for this suggestion and agree that a table comparing the pros and cons of all existing methods would be helpful for the general reader and also highlight the key advantages of our new approach. A table comparing previous methods for var gene and transcript characterisation has been added to the manuscript and is referenced in the introduction (line 107).

## Author response table 1.

Comparison of previous var assembly approaches based on DNA- and RNA-sequencing.

Study	Assembler	k-mer	Transcript or gene assembly	Validation on reference strain(s) (Yes/No)	Validation on field strain(s) (Yes/No)	Validation across different expression levels (Yes/No)	Read length (Short/Long)	Read correction (Yes/No)	Scaffolding (Yes/No)	Var transcript filter approach	Assumption	Other limitations
Duffy et al., 2016	Oases		Transcript	No	No	No	Short	Yes	Yes	Aligned to 399 var genes with BLAST (e-value < 10 <sup>-4</sup> )		- No quantification of misassemblies - Unable to recover full length transcript assemblies - Requires prior filtering of human DNA
Dane et al., 2017	Sprai and Celere (no longer maintained)	71	Gene	Yes (strain NF54)	Yes (12 LM patient samples)	NA – only genome assemblies	Long and short	Method assumes combination of long and short-read sequencing will identify errors	No	>500bp and aligned to VarCom database	Assumes a whole genome assembly is available	- Need a combination of short-read and long-read sequencing - Unable to fully resolve H-terminus - No quantification of misassemblies
Tonkin-Hill et al., 2018*	SoapDenovo-Tiers	21, 31, 41, 52 & 61	Transcript	Yes (strain TG)	No	No	Short	No	No	>500bp and containing a sig. annotated var domain		- No quantification of misassemblies - Performs de novo assembly on all non-human and P. falciparum reads - Inconsistent results in 5 samples when comparing genomic and RNA-seq results for dominant var gene
Otto et al., 2019	Maasru + post-assembly improvements	Default	Gene	Yes (clone 3D7)	Yes (15 PFSK reference genomes)	No	Short	Yes	Yes		Whole genome dataset	
Andrade et al., 2020	Velvet	41	Transcript	No	No	No	Short	No	No	Aligned to VarCom database		- No quantification of misassemblies - Performs de novo assembly on all non-human and P. falciparum reads - Inconsistent results in 5 samples when comparing genomic and RNA-seq results for dominant var gene
Stucke et al., 2021	maSPAdes	Default	Transcript	No	Yes (5 LM patient samples)	No – only the most expressed var genes	Short	Yes	Unclear	> 500bp and containing a sig. annotated var domain	Information about the true var annotation is available	

\* also used in Wichien et al., 2021; Gullickson et al., 2022  
LM: uncomplicated malaria

**Reviewer #3:**

*This work focuses on the important problem of how to access the highly polymorphic var gene family using short-read sequence data. The approach that was most successful, and utilized for all subsequent analyses, employed a different assembler from their prior pipeline, and impressively, more than doubles the N50 metric.*

*The authors then endeavor to utilize these improved assemblies to assess differential RNA expression of ex vivo and short-term cultured samples, and conclude that their results "cast doubt on the validity" of using short-term cultured parasites to infer in vivo characteristics. Readers should be aware that the various approaches to assess differential expression lack statistical clarity and appear to be contradictory. Unfortunately, there is no attempt to describe the rationale for the different approaches and how they might inform one another.*

*It is unclear whether adjusting for life-cycle stage as reported is appropriate for the var-only expression models. The methods do not appear to describe what type of correction variable (continuous/categorical) was used in each model, and there is no discussion of the impact on var vs. core transcriptome results.*

We agree with the reviewer that the different methods and results of the var transcriptome analysis can be difficult to reconcile. To address this, we have included a summary table with a brief description of the rationale and results of each approach in our analysis pipeline.

**Author response table 2.**

Summary of the different levels of analysis performed to assess the effect of short-term parasite culturing on var and core gene expression, their rationale, method, results, and interpretation.

Analysis level	Analysis	Rationale	Method	Results	Interpretation
var transcript	Per patient expression ranking	Relative quantification of var transcripts over consecutive generations of parasites originating from the same patient to reveal var gene switching events	Combine assembled var transcripts for each patient into a reference and quantify expression, validated with DBLα-tag analysis	46% of the patient samples had a change in the dominant or top 3 highest expressed var gene	Modest changes in most samples, but unpredictable var gene switching during culture in some samples
	Per patient var expression homogeneity (VEH)	Determine the overall diversity of var gene expression (number of different variants expressed and their abundance) to assess impact of culturing on the overall var gene expression pattern	Comparison of diversity curves based on per patient quantification of the var transcriptome	36% of ex vivo samples diversity curves distinct from in vitro samples	Some patient samples underwent a much greater var transcriptional change compared to others
	Conserved var variants	Assessing and comparing the expression levels of strain-transcendent var gene variants (var1, var2csc, var3) between samples	Reference of all assembled transcripts for each conserved var gene and quantify expression	var2csc expression increases in 2nd in vitro generation	Parasites converge to var2csc during short-term in vitro culture
var-encoded PLEMP1 domains	Differential expression of PLEMP1 domains	Identification, quantification and comparison of expression levels of different var gene-encoded PLEMP1 domains associated with different disease manifestations	Pool all assembled var transcripts into a reference and quantify expression of each domain	46% of the ex vivo samples cluster away from their in vitro samples in PCA plots, distinct clustering by in vitro generation was not observed; CIDRa2.5 significantly differentially expressed between ex vivo and generation 1	Transition to culture results in modest modulation of particular var domains
var group	Expression of NTS (NTSA vs NTSB) and DBLα (DBLα1 vs DBLα0+ DBLα2)	Quantification and comparison of expression levels of different var gene groups (group A vs. group B and C)	Create a reference of all assembled DBLα and NTS domains for each patient and quantify expression. Validated with DBLα-tag analysis	No significant changes	No preferential up or down regulation of certain var groups during transition to culture
Global var expression	LARSFADIG coverage	Assessing the overall var gene expression level (excluding var2csc)	Assemble the LARSFADIG motif and map non-core reads to quantify coverage	Trend for decrease in global var expression during culture, but no significant changes	Subtle reduction in global var gene expression may reflect increase in parasite age during culture
Core genes	Differential gene expression (DGE)	Assessing the impact of cultivation on the parasite core gene transcriptome	Differential expression analysis of core genes (P. falciparum 3D7 used as reference)	19% of the core transcriptome significantly differentially expressed between paired ex vivo and generation 1 in vitro samples; distinct clustering by parasite generation observed; upregulation of invasion and replication related genes in vitro	Parasites core gene expression changes substantially upon entering culture

Additionally, the var transcript differential expression analysis was removed from the manuscript, because this study was in a unique position to perform a more focused analysis of var transcriptional changes across paired samples, meaning the per-patient approach was



more suitable. This allowed for changes in the var transcriptome to be identified that would have gone unnoticed in the traditional differential expression analysis.

We thank the reviewer for his highly important comment about adjusting for life cycle stage. Var gene expression is highly stage-dependent, so any quantitative comparison between samples does need adjustment for developmental stage. All life cycle stage adjustments were done using the mixture model proportions to be consistent with the original paper, described in the results and methods sections:

- Line 219–221: “Due to the potential confounding effect of differences in stage distribution on gene expression, we adjusted for developmental stage determined by the mixture model in all subsequent analyses.”
- Line 722–725: “Var gene expression is highly stage dependent, so any quantitative comparison between samples needs adjustment for developmental stage. The life cycle stage proportions determined from the mixture model approach were used for adjustment.”

The rank-expression analysis did not have adjustment for life cycle stage as the values were determined as a percentage contribution to the total var transcriptome. The var group level and the global var gene expression analyses were adjusted for life cycle stages, by including them as an independent variable, as described in the results and methods sections.

Var group expression:

- Line 321–326: “Due to these results, the expression of group A var genes vs. group B and C var genes was investigated using a paired analysis on all the DBL $\alpha$  (DBL $\alpha$ 1 vs DBL $\alpha$ 0 and DBL $\alpha$ 2) and NTS (NTS $\alpha$  vs NTS $\beta$ ) sequences assembled from ex vivo samples and across multiple generations in culture. A linear model was created with group A expression as the response variable, the generation and life cycle stage as independent variables and the patient information included as a random effect. The same was performed using group B and C expression levels.”
- Line 784–787: “DESeq2 normalisation was performed, with patient identity and life cycle stage proportions included as covariates and differences in the amounts of var transcripts of group A compared with groups B and C assessed (Love et al., 2014). A similar approach was repeated for NTS domains.”

Global var gene expression:

- Line 342–347: “A linear model was created (using only paired samples from ex vivo and generation 1) (Supplementary file 1) with proportion of total gene expression dedicated to var gene expression as the response variable, the generation and life cycle stage as independent variables and the patient information included as a random effect. This model showed no significant differences between generations, suggesting that differences observed in the raw data may be a consequence of small changes in developmental stage distribution in culture.”
- Line 804–806: “Significant differences in total var gene expression were tested by constructing a linear model with the proportion of gene expression dedicated to var gene expression as the response variable, the generation and life cycle stage as an independent variables and the patient identity included as a random effect.”

The analysis of the conserved var gene expression was adjusted for life cycle stage:

- Line 766–768: “For each conserved gene, Salmon normalised read counts (adjusted for life cycle stage) were summed and expression compared across the generations using a pairwise Wilcoxon rank test.”

And life cycle stage estimates were included as covariates in the design matrix for the domain differential expression analysis:

- Line 771–773: “DESeq2 was used to test for differential domain expression, with five expected read counts in at least three patient isolates required, with life cycle stage and patient identity used as covariates.”

**Reviewer #1:**

1. *In the legend to Figure 1, the authors cite "Deitsch and Hviid, 2004" for the classification of different var gene types. This is not the best reference for this work. Better citations would be Kraemer and Smith, Mol Micro, 2003 and Lavstsen et al, Malaria J, 2003.*

We agree and have updated the legend in Figure 1 with these references, consistent with the references cited in the introduction.

1. *In Figures 2 and 3, each of the boxes in the flow charts are largely filled with empty space while the text is nearly too small to read. Adjusting the size of the text would improve legibility.*

We have increased the size of the text in these figures.

1. *My understanding of the computational method for assessing global var gene expression indicates an initial step of identifying reads containing the amino acid sequence LARSFADIG. It is worth noting that VAR2CSA does not contain this motif. Will the pipeline therefore miss expression of this gene, and if so, how does this affect the assessment of global var gene assessment? This seems relevant given that the authors detect increased expression of var2csa during adaptation to culture.*

To address this question, we have added an explanation in the methods section to better explain our analysis. Var2csa was not captured in the global var gene expression analysis, but was analyzed separately because of its unique properties (conservation, proposed role in regulating var gene switching, slightly divergent timing of expression, translational repression).

- Line 802/3: “Var2csa does not contain the LARSFADIG motif, hence this quantitative analysis of global var gene expression excluded var2csa (which was analysed separately).”

1. *In Figures 4 and 7, panels a and b display virtually identical PCA plots, with the exception that panel A displays more generations. Why are both panels included? There doesn't appear to be any additional information provided by panel B.*

We agree and have removed Figure 7b for the core transcriptome PCA as it did not provide any new information. The var transcript differential analysis (displayed in Figure 4) has been removed from the manuscript.

1. On line 560-567, the authors state "However, the impact of short-term culture was the most apparent at the var transcript level and became less clear at higher levels." What are the high levels being referred to here?

We have replaced this sentence to make it clearer what the different levels are (global var gene expression, var domain and var type).

- Line 526/7: "However, the impact of short-term culture was the most apparent at the var transcript level and became less clear at the var domain, var type and global var gene expression level."

**Reviewer #2:**

*The authors make no mention or assessment of previously published var gene assembly methods from clinical samples that focus on genomic or transcriptomic approaches. These include:*

<https://pubmed.ncbi.nlm.nih.gov/28351419/>

<https://pubmed.ncbi.nlm.nih.gov/34846163/>

*These methods should be compared to the method for var gene assembly outlined by the co-authors, especially as the authors say that their method "overcomes previous limitations and outperforms current methods" (128-129). The second reference above appears to be a method to measure var expression in clinical samples and so should be particularly compared to the approach outlined by the authors.*

Thank you for pointing this out. We have included the second reference in the introduction of our revised manuscript, where we refer to var assembly and quantification from RNA-sequencing data. We abstained from including the first paper in this paragraph (Dara et al., 2017) as it describes a var gene assembly pipeline and not a var transcript assembly pipeline.

- Line 101–105: "While approaches for var assembly and quantification based on RNA-sequencing have recently been proposed (Wichers et al., 2021; Stucke et al., 2021; Andrade et al., 2020; TonkinHill et al., 2018, Duffy et al., 2016), these still produce inadequate assembly of the biologically important N-terminal domain region, have a relatively high number of misassemblies and do not provide an adequate solution for handling the conserved var variants (Table S1)."

Additionally, we have updated the manuscript with a table (Table S1) comparing these two methods plus other previously used var transcript/gene assembly approaches (see comment to the public reviews).

But to address this particular comment in more detail, the first paper (Dara et al., 2017) is a var gene assembly pipeline and not a var transcript assembly pipeline. It is based on assembling var exon 1 from unfished whole genome assemblies of clinical samples and requires a prior step for filtering out human DNA. The authors used two different assemblers, Celera for short reads (which is no longer maintained) and Sprai for long reads (>2000bp), but found that Celera performed worse than Sprai, and subsequently used Sprai assemblies. Therefore, this method does not appear to be suitable for assembling short reads from RNA-seq.

The second paper (Stucke et al. 2021) focusses more on enriching for parasite RNA, which precedes assembly. The capture method they describe would complement downstream

analysis of var transcript assembly with our pipeline. Their assembly pipeline is similar to our pipeline as they also performed de novo assembly on all *P. falciparum* mapping and non-human mapping reads and used the same assembler (but with different parameters). They clustered sequences using the same approach but at 90% sequence identity as opposed to 99% sequence identity using our approach. Then, Stucke et al. use 500nt as a cut-off as opposed to the more stringent filtering approach used in our approach. They annotated their de novo assembled transcripts with the known amino acid sequences used in their design of the capture array; our approach does not assume prior information on the var transcripts. Finally, their approach was validated only for its ability to recover the most highly expressed var transcript in 6 uncomplicated malaria samples, and they did not assess mis-assemblies in their approach.

*For the methods (619–621), were erythrocytes isolated by Ficoll gradient centrifugation at the time of collection or later?*

We have updated the methods section to clarify this.

- Line 586–588: “Blood was drawn and either immediately processed (#1, #2, #3, #4, #11, #12, #14, #17, #21, #23, #28, #29, #30, #31, #32) or stored overnight at 4°C until processing (#5, #6, #7, #9, #10, #13, #15, #16, #18, #19, #20, #22, #24, #25, #26, #27, #33).”

*Was the current pipeline and assembly method assessed for var chimeras? This should be described.*


Yes, this was quantified in the Pf 3D7 dataset and also assessed in the German traveler dataset. For the 3D7 dataset it is described in the result section and Figure S1.

- Line 168–174: “However, we found high accuracies ( $> 0.95$ ) across all approaches, meaning the sequences we assembled were correct (Figure 2 – Figure supplement 1b). The whole transcript approach also performed the best when assembling the lower expressed var genes (Figure 2 – Figure supplement 1e) and produced the fewest var chimeras compared to the original approach on *P. falciparum* 3D7. Fourteen misassemblies were observed with the whole transcript approach compared to 19 with the original approach (Table S2). This reduction in misassemblies was particularly apparent in the ring-stage samples.” - Figure S1:

### Author response image 1.

Performance of novel computational pipelines for var assembly on *Plasmodium falciparum* 3D7: The three approaches (whole transcript: blue, domain approach: orange, original approach: green) were applied to a public RNA-seq dataset (ENA: PRJEB31535) of the intra-erythrocytic life cycle stages of 3 biological replicates of cultured *P. falciparum* 3D7, sampled at 8-hour intervals up until 40hrs post infection (bpi) and then at 4-hour intervals up until 48 (Wichers et al., 2019). Boxplots show the data from the 3 biological replicates for each time point in the intra-erythrocytic life cycle: a) alignment scores for the dominantly expressed var gene (PF3D7\_07126m), b) accuracy scores for the dominantly var gene (PF3D7\_0712600), c) number of contigs to assemble the dominant var gene (PF3D7\_0712600), d) alignment scores for a middle ranking expressed var gene (PF3D7\_0937800), e) alignment scores for the lowest expressed var gene (PF3D7\_0200100). The first best blast hit (significance threshold =  $1e-10$ ) was chosen for each contig. The alignment score was used to evaluate the each method. The alignment score represents  $\sqrt{\text{accuracy} \times \text{recovery}}$ . The accuracy is the proportion of bases that are correct in the assembled transcript and the recovery reflects what proportion of the true transcript was assembled. Assembly completeness of the dominant var gene (PF3D7\_071200, length = 6648nt) for the three approaches was assessed for each biological f) biological

replicate 1, g) biological replicate 2, h) biological replicate 3. Dotted lines represent the start and end of the contigs required to assemble the vargene. Red bars represent assembled sequences relative to the dominantly whole vargene sequence, where we know the true sequence (termed “reference transcript”).



For the ex vivo samples, this has been discussed in the result section and now we also added this information to Table 1.

- Line 182/3: “Remarkably, with the new whole transcript method, we observed a significant decrease (2 vs 336) in clearly misassembled transcripts with, for example, an N-terminal domain at an internal position.”
- Table 1:

### Author response table 3.

Statistics for the different approaches used to assemble the var transcripts. Var assembly approaches were applied to malaria patient ex vivo samples (n=32) from (Wichers et al., 2021) and statistics determined. Given are the total number of assembled var transcripts longer than 500 nt containing at least one significantly annotated var domain, the maximum length of the longest assembled var transcript in nucleotides and the N50 value, respectively.

The N50 is defined as the sequence length of the shortest var contig, with all var contigs greater than or equal to this length together accounting for 50% of the total length of concatenated var transcript assemblies. Misassemblies represents the number of misassemblies for each approach. \*\*Number of misassemblies were not determined for the domain approach due to its poor performance in other metrics.

	Total no. contigs ≥500nts	Maximum length (nt)	Average contig length (nt)	N50	Misassemblies
Original approach	6,441	10,412	1,621	2,302	336
Domain approach	4,691	5,003	954	1,088	NA**
Whole transcript approach	3,011	12,586	2,771	5,381	2

Line 432: "the core gene transcriptome underwent a greater change relative to the var transcriptome upon transition to culture." Can this be shown statistically? It's unclear whether the difference in the sizes of the respective pools of the core genome and the var genes may account for this observation.

We found 19% of the core transcriptome to be differentially expressed. The per patient var transcript analysis revealed individually highly variable but generally rather subtle changes in the var transcriptome. The different methods for assessing this make it difficult to statistically compare these two different results.

The feasibility of this approach for field samples should be discussed in the Discussion.

In the original manuscript we reflected on this already several times in the discussion (e.g., line 465/6; line 471–475; line 555–568). We now have added another two sentences at the end of the paragraph starting in line 449 to address this point. It reads now:

- Line 442–451: "Our new approach used the most geographically diverse reference of var gene sequences to date, which improved the identification of reads derived from var transcripts. This is crucial when analysing patient samples with low parasitaemia where var transcripts are hard to assemble due to their low abundance (Guillochon et al., 2022). Our approach has wide utility due to stable performance on both laboratory-adapted and clinical samples. Concordance in the different var expression profiling approaches (RNA-sequencing and DBLα-tag) on ex vivo samples increased using the new approach by 13%, when compared to the original approach (96% in the whole transcript approach compared to 83% in Wichers et al., 2021). This suggests the new approach provides a more accurate method for characterising var genes, especially in samples collected directly from patients. Ultimately, this will allow a deeper understanding of relationships between var gene expression and clinical manifestations of malaria."

MINOR

The plural form of PfEMP1 (PfEMP1s) is inconsistently used throughout the text.

Corrected.

404-405: statistical test for significance?

Thank you for this suggestion. We have done two comparisons between the original analysis from Wichers et al., 2021 and our new whole transcript approach to test concordance of the RNAseq approaches with the DBLα-tag approach using paired Wilcoxon tests. These



comparisons suggest that our new approach has significantly increased concordance with DBL $\alpha$ -tag data and might be better at capturing all expressed DBL $\alpha$  domains than the original analysis (and the DBL $\alpha$ -approach), although not statistically significant. We describe this now in the result section.

- Line 352–361: “Overall, we found a high agreement between the detected DBL $\alpha$ -tag sequences and the de novo assembled var transcripts. A median of 96% (IQR: 93–100%) of all unique DBL $\alpha$ -tag sequences detected with >10 reads were found in the RNA-sequencing approach. This is a significant improvement on the original approach ( $p=0.0077$ , paired Wilcoxon test), in which a median of 83% (IQR: 79–96%) was found (Wichers et al., 2021). To allow for a fair comparison of the >10 reads threshold used in the DBL $\alpha$ -tag approach, the upper 75th percentile of the RNA-sequencing assembled DBL $\alpha$  domains were analysed. A median of 77.4% (IQR: 61–88%) of the upper 75th percentile of the assembled DBL $\alpha$  domains were found in the DBL $\alpha$ -tag approach. This is a lower median percentage than the median of 81.3% (IQR: 73–98%) found in the original analysis ( $p=0.28$ , paired Wilcoxon test) and suggests the new assembly approach is better at capturing all expressed DBL $\alpha$  domains.”

Figure 4: The letters for the figure panels need to be added.


The figure has been removed from the manuscript.

### Reviewer #3:

*It is difficult from Table S2 to determine how many unique var transcripts would have enough coverage to be potentially assembled from each sample. It seems unlikely that 455 distinct vars (~14 per sample) would be expressed at a detectable level for assembly. Why not DNA-sequence these samples to get the full repertoire for comparison to RNA? Why would so many distinct transcripts be yielded from fairly synchronous samples?*

We know from controlled human malaria infections of malaria-naïve volunteers, that most var genes present in the genomic repertoire of the parasite strain are expressed at the onset of the human blood phase (heterogeneous var gene expression) (Wang et al., 2009; Bachmann et al., 2016; Wichers-Misterek et al., 2023). This pattern shifts to a more restricted, homogeneous var expression pattern in semi-immune individuals (expression of few variants) depending on the degree of immunity (Bachmann et al., 2019).

### Author response image 2.



In this cohort, 15 first-time infections are included, which should also possess a more heterogeneous var gene expression in comparison to the pre-exposed individuals, and indeed such a trend is already seen in the number of different DBL $\alpha$ -tag clusters found in both

patient groups (see figure panel from Wichers et al. 2021: blue-first-time infections; grey-pre-exposed). Moreover, Warimwe et al. 2013 have shown that asymptomatic infections have a more homogeneous var expression in comparison to symptomatic infections. Therefore, we expect that parasites from symptomatic infections have a heterogeneous var expression pattern with multiple var gene variants expressed, which we could assemble due to our high read depth and our improved var assembly pipeline for even low expressed variants.

Moreover, the distinct transcripts found in the RNA-seq approach were confirmed with the DBLα tag data. To our opinion, previous approaches may have underestimated the complexity of the var transcriptome in less immune individuals.


*Mapping reads to these 455 putative transcripts and using this count matrix for differential expression analysis seems very unlikely to produce reliable results. As acknowledged on line 327, many reads will be mis-mapped, and perhaps most challenging is that most vars will not be represented in most samples. In other words, even if mapping were somehow perfect, one would expect a sparse matrix that would not be suitable for statistical comparisons between groups. This is likely why the per-patient transcript analysis doesn't appear to be consistent. I would recommend the authors remove the DE sections utilizing this approach, or add convincing evidence that the count matrix is useable.*

We agree that this is a general issue of var differential expression analysis. Therefore, we have removed the var differential expression analysis from this manuscript as the per patient approach was more appropriate for the paired samples. We validated different mapping strategies (new Figure S6) and included a paragraph discussing the problem in the result section:

- Line 237–255: “In the original approach of Wichers et al., 2021, the non-core reads of each sample used for var assembly were mapped against a pooled reference of assembled var transcripts from all samples, as a preliminary step towards differential var transcript expression analysis. This approach returned a small number of var transcripts which were expressed across multiple patient samples (Figure 3 – Figure supplement 2a). As genome sequencing was not available, it was not possible to know whether there was truly overlap in var genomic repertoires of the different patient samples, but substantial overlap was not expected. Stricter mapping approaches (for example, excluding transcripts shorter than 1500nt) changed the resulting var expression profiles and produced more realistic scenarios where similar var expression profiles were generated across paired samples, whilst there was decreasing overlap across different patient samples (Figure 3 – Figure supplement 2b,c). Given this limitation, we used the paired samples to analyse var gene expression at an individual subject level, where we confirmed the MSP1 genotypes and alleles were still present after short-term in vitro cultivation. The per patient approach showed consistent expression of var transcripts within samples from each patient but no overlap of var expression profiles across different patients (Figure 3 – Figure supplement 2d). Taken together, the per patient approach was better suited for assessing var transcriptional changes in longitudinal samples. It has been hypothesised that more conserved var genes in field isolates increase parasite fitness during chronic infections, necessitating the need to correctly identify them (Dimonte et al., 2020, Otto et al., 2019). Accordingly, further work is needed to optimise the pooled sample approach to identify truly conserved var transcripts across different parasite isolates in cross-sectional studies.” - Figure S6:

### Author response image 3.

Var expression profiles across different mapping. Different mapping approaches were used to quantify the Var expression profiles of each sample (ex Vivo (n=13), generation I (n=13), generation 2 (n=10) and generation 3 (n=1)). The pooled sample approach in which all significantly assembled var transcripts (1500nt and containing 3 significantly annotated var domains) across samples were combined into a reference and redundancy was removed using cd-hit (at sequence identity = 99%) (a—c). The non-core reads of each sample were mapped to this pooled reference using a) Salmon, b) bowtie2 filtering for uniquely mapping paired reads with MAPQ and c) bowtie2 filtering for uniquely mapping paired reads with a MAPQ > 20. d) The per patient approach was applied. For each patient, the paired ex vivo and in vitro samples were analysed. The assembled var transcripts (at least 1500nt and containing 3 significantly annotated var domains) across all the generations for a patient were combined into a reference, redundancy was removed using cd-hit (at sequence identity: 99%), and expression was quantified using Salmon. Pie charts show the var expression profile with the relative size of each slice representing the relative percentage of total var gene expression of each var transcript. Different colours represent different assembled var transcripts with the same colour code used across a-d.



For future cross-sectional studies a per patient analysis that attempts to group per patient assemblies on some unifying structure (e.g., domain, homology blocks, domain cassettes etc) should be performed.

*Line 304. I don't understand the rationale for comparing naïve vs. prior-exposed individuals at ex-vivo and gen 1 timepoints to provide insights into how reliable cultured parasites are as a surrogate for var expression in vivo. Further, the next section (per patient) appears to confirm the significant limitation of the 'all sample analysis' approach. The conclusion on line 319 is not supported by the results reported in figures S9a and S9b, nor is the bold conclusion in the abstract about "casting doubt" on experiments utilizing culture adapted*

We have removed this comparison from the manuscript due to the inconsistencies with the var per patient approach. However, the conclusion in the abstract has been rephrased to reflect the fact we observed 19% of the core transcript differentially expressed within one cycle of cultivation.

*Line 372/391 (and for the other LMM descriptions). I believe you mean to say response variable, rather than explanatory variable. Explanatory variables are on the right hand side of the equation.*

Thank you for spotting this inaccuracy, we changed it to “response variable” (line 324, line 343, line 805).

*Line 467. Similar to line 304, why would comparisons of naïve vs. prior-exposed be informative about surrogates for in vivo studies? Without a gold-standard for what should be differentially expressed between naïve and prior-exposed in vivo, it doesn't seem prudent to interpret a drop in the number of DE genes for this comparison in generation 1 as evidence that biological signal for this comparison is lost. What if the generation 1 result is actually more reflective of the true difference in vivo, but the ex vivo samples are just noisy? How do we know? Why not just compare ex vivo vs generation 1/2 directly (as done in the first DE analysis), and then you can comment on the large number of changes as samples are less and less proximal to in vivo?*

In the original paper (Wichers et al., 2021), there were differences between the core transcriptome of naïve vs previously exposed patients. However, these differences appeared to diminish in vitro, suggesting the in vivo core transcriptome is not fully maintained in vitro.

We have added a sentence explaining the reasoning behind this analysis in the results section:

- Lines 414–423: “In the original analysis of ex vivo samples, hundreds of core genes were identified as significantly differentially expressed between pre-exposed and naïve malaria patients. We investigated whether these differences persisted after in vitro cultivation. We performed differential expression analysis comparing parasite isolates from naïve (n=6) vs pre-exposed (n=7) patients, first between their ex vivo samples, and then between the corresponding generation 1 samples. Interestingly, when using the ex vivo samples, we observed 206 core genes significantly upregulated in naïve patients compared to pre-exposed patients (Figure 7 – Figure supplement 3a). Conversely, we observed no differentially expressed genes in the naïve vs pre-exposed analysis of the paired generation 1 samples (Figure 7 – Figure supplement 3b). Taken together with the preceding findings, this suggests one cycle of cultivation shifts the core transcriptomes of parasites to be more alike each other, diminishing inferences about parasite biology in vivo.”

*Overall, I found the many DE approaches very frustrating to interpret coherently. If not dropped in revision, the reader would benefit from a substantial effort to clarify the rationale for each approach, and how each result fits together with the other approaches and builds to a concise conclusion.*

We agree that the manuscript contains many different complex layers of analysis and that it is therefore important to explain the rationale for each approach. Therefore, we now included the summary Table 3 (see comment to public review). Additionally, we have removed the var transcript differential expression due to its limitations, which we hope has already streamlined our manuscript.